<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathogens</journal-id><journal-id journal-id-type="iso-abbrev">Pathogens</journal-id><journal-id journal-id-type="pmc-domain-id">2622</journal-id><journal-id journal-id-type="pmc-domain">pathogens</journal-id><journal-id journal-id-type="publisher-id">pathogens</journal-id><journal-title-group><journal-title>Pathogens</journal-title></journal-title-group><issn pub-type="epub">2076-0817</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9025045</article-id><article-id pub-id-type="pmcid-ver">PMC9025045.1</article-id><article-id pub-id-type="pmcaid">9025045</article-id><article-id pub-id-type="pmcaiid">9025045</article-id><article-id pub-id-type="pmid">35456106</article-id><article-id pub-id-type="doi">10.3390/pathogens11040431</article-id><article-id pub-id-type="publisher-id">pathogens-11-00431</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The History of Live Attenuated <italic toggle="yes">Centrin</italic> Gene-Deleted <italic toggle="yes">Leishmania</italic> Vaccine Candidates</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1112-7715</contrib-id><name name-style="western"><surname>Volpedo</surname><given-names initials="G">Greta</given-names></name><xref rid="af1-pathogens-11-00431" ref-type="aff">1</xref><xref rid="fn1-pathogens-11-00431" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names initials="P">Parna</given-names></name><xref rid="af2-pathogens-11-00431" ref-type="aff">2</xref><xref rid="fn1-pathogens-11-00431" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gannavaram</surname><given-names initials="S">Sreenivas</given-names></name><xref rid="af2-pathogens-11-00431" ref-type="aff">2</xref><xref rid="fn1-pathogens-11-00431" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pacheco-Fernandez</surname><given-names initials="T">Thalia</given-names></name><xref rid="af1-pathogens-11-00431" ref-type="aff">1</xref><xref rid="fn1-pathogens-11-00431" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oljuskin</surname><given-names initials="T">Timur</given-names></name><xref rid="af2-pathogens-11-00431" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dey</surname><given-names initials="R">Ranadhir</given-names></name><xref rid="af2-pathogens-11-00431" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Satoskar</surname><given-names initials="AR">Abhay R.</given-names></name><xref rid="af1-pathogens-11-00431" ref-type="aff">1</xref><xref rid="c1-pathogens-11-00431" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakhasi</surname><given-names initials="HL">Hira L.</given-names></name><xref rid="af2-pathogens-11-00431" ref-type="aff">2</xref><xref rid="c1-pathogens-11-00431" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Chang</surname><given-names initials="KP">Kwang Poo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pathogens-11-00431"><label>1</label>Departments of Pathology and Microbiology, Wexner Medical Center, The Ohio State University, Columbus, OH 43201, USA; <email>volpedo.1@buckeyemail.osu.edu</email> (G.V.); <email>thalia.pachecofernandez@osumc.edu</email> (T.P.-F.)</aff><aff id="af2-pathogens-11-00431"><label>2</label>Division of Emerging and Transfusion Transmitted Disease, Center for Biologics Evaluation and Research Food and Drug Administration, Silver Spring, MD 20993, USA; <email>parna.bhattacharya@fda.hhs.gov</email> (P.B.); <email>sreenivas.gannavaram@fda.hhs.gov</email> (S.G.); <email>timur.oljuskin@usda.gov</email> (T.O.); <email>ranadhir.dey@fda.hhs.gov</email> (R.D.)</aff><author-notes><corresp id="c1-pathogens-11-00431"><label>*</label>Correspondence: <email>abhay.satoskar@osumc.edu</email> (A.R.S.); <email>hira.nakhasi@fda.hhs.gov</email> (H.L.N.)</corresp><fn id="fn1-pathogens-11-00431"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2022</year></pub-date><volume>11</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">405847</issue-id><elocation-id>431</elocation-id><history><date date-type="received"><day>07</day><month>3</month><year>2022</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>04</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>23</day><month>04</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-12 05:25:14.057"><day>12</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pathogens-11-00431.pdf"/><abstract><p>Leishmaniasis, caused by an infection of the <italic toggle="yes">Leishmania</italic> protozoa, is a neglected tropical disease and a major health problem in tropical and subtropical regions of the world, with approximately 350 million people worldwide at risk and 2 million new cases occurring annually. Current treatments for leishmaniasis are not highly efficacious and are associated with high costs, especially in low- and middle-income endemic countries, and high toxicity. Due to a surge in the incidence of leishmaniases worldwide, the development of new strategies such as a prophylactic vaccine has become a high priority. However, the ability of <italic toggle="yes">Leishmania</italic> to undermine immune recognition has limited our efforts to design safe and efficacious vaccines against leishmaniasis. Numerous antileishmanial vaccine preparations based on DNA, subunit, and heat-killed parasites with or without adjuvants have been tried in several animal models but very few have progressed beyond the experimental stage. However, it is known that people who recover from <italic toggle="yes">Leishmania</italic> infection can be protected lifelong against future infection, suggesting that a successful vaccine requires a controlled infection to develop immunologic memory and subsequent long-term immunity. Live attenuated <italic toggle="yes">Leishmania</italic> parasites that are non-pathogenic and provide a complete range of antigens similarly to their wild-type counterparts could evoke such memory and, thus, would be effective vaccine candidates. Our laboratory has developed several live attenuated <italic toggle="yes">Leishmania</italic> vaccines by targeted <italic toggle="yes">centrin</italic> gene disruptions either by homologous recombination or, more recently, by using genome editing technologies involving CRISPR-Cas9. In this review, we focused on the sequential history of <italic toggle="yes">centrin</italic> gene-deleted <italic toggle="yes">Leishmania</italic> vaccine development, along with the characterization of its safety and efficacy. Further, we discussed other major considerations regarding the transition of dermotropic live attenuated <italic toggle="yes">centrin</italic> gene-deleted parasites from the laboratory to human clinical trials.</p></abstract><kwd-group><kwd><italic toggle="yes">Leishmania</italic></kwd><kwd>visceral leishmaniasis</kwd><kwd>vaccine</kwd><kwd>live attenuated parasite vaccines</kwd><kwd>pan-<italic toggle="yes">Leishmania</italic> vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pathogens-11-00431"><title>1. Introduction</title><p>Leishmaniasis is the disease caused by the protozoan parasite <italic toggle="yes">Leishmania</italic> comprised of dozens of species of unicellular protozoan parasites. <italic toggle="yes">Leishmania</italic> parasites exhibit a diheteroxenous life cycle consisting of their bloodsucking sandfly insect host, which serves as a vector, and their primary vertebrate hosts [<xref rid="B1-pathogens-11-00431" ref-type="bibr">1</xref>]. The disease manifests in one of three main types that can be further divided into subtypes depending on the clinical manifestations. The three main types of leishmaniasis are cutaneous (CL), mucocutaneous (MCL), and visceral (VL), which are respectively characterized by lesions on the skin; destruction of the mucosa of the mouth, nose, and throat; or a potentially fatal infection of the visceral organs especially the spleen, liver, and bone marrow resulting in splenomegaly and hepatosplenomegaly. The type of pathology a host develops depends on the species of <italic toggle="yes">Leishmania</italic> and the interaction of that parasite with the host immune system [<xref rid="B2-pathogens-11-00431" ref-type="bibr">2</xref>,<xref rid="B3-pathogens-11-00431" ref-type="bibr">3</xref>,<xref rid="B4-pathogens-11-00431" ref-type="bibr">4</xref>]. Leishmaniasis is one of the top neglected tropical diseases (NTD) tracked by the World Health Organization (WHO) with an estimated 1 billion people at risk for infection and approximately 1.7 million infections occurring throughout 98 tropical and subtropical countries per annum [<xref rid="B5-pathogens-11-00431" ref-type="bibr">5</xref>,<xref rid="B6-pathogens-11-00431" ref-type="bibr">6</xref>]. An estimated 70,000 deaths per year also occur due to VL [<xref rid="B2-pathogens-11-00431" ref-type="bibr">2</xref>,<xref rid="B3-pathogens-11-00431" ref-type="bibr">3</xref>]. Leishmaniasis can be geographically divided into Old World and New World leishmaniasis, depending on the species causing the disease.</p><p>Treatment schemas for leishmaniasis consist mainly of various chemotherapies. Pentavalent antimonials (Sb<sup>5+</sup>) were the first chemotherapy drugs to be developed and used for the treatment of leishmaniasis [<xref rid="B7-pathogens-11-00431" ref-type="bibr">7</xref>]. However, after several decades of use, drug resistance to antimonial treatments has rendered them ineffective in many cases [<xref rid="B2-pathogens-11-00431" ref-type="bibr">2</xref>,<xref rid="B7-pathogens-11-00431" ref-type="bibr">7</xref>]. Several other drugs have been developed in response to antimonial drug resistance in <italic toggle="yes">Leishmania</italic> including Amphotericin B, pentamidine isethionate, miltefosine, and paromomycin [<xref rid="B7-pathogens-11-00431" ref-type="bibr">7</xref>]. The antimonial drugs and those developed as alternatives cause many side effects and do not always provide a clinical cure of leishmaniasis. At times, patients with severe side effects need to cease treatment until they recover and then slowly resume [<xref rid="B2-pathogens-11-00431" ref-type="bibr">2</xref>]. No vaccine is approved for use in humans to prevent leishmaniasis and many attempts to formulate a vaccine have failed in preclinical studies or did not demonstrate efficacy in phase I/II clinical trials [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. Fortunately, cutaneous leishmaniasis can be treated with thermotherapy, but this is not feasible in the other forms of the disease [<xref rid="B9-pathogens-11-00431" ref-type="bibr">9</xref>]. These observations highlight the need of a successful <italic toggle="yes">Leishmania</italic> vaccine to alleviate the disease burden of leishmaniasis and avoid chemotherapies with high toxicity. Further, the World Health Organization and other regional authorities have set goals to achieve the elimination of leishmaniasis using various strategies. Therefore, the development of a safe and efficacious vaccine could help achieve the <italic toggle="yes">Leishmania</italic> elimination program. </p></sec><sec id="sec2-pathogens-11-00431"><title>2. Vaccination Strategies against Leishmaniasis</title><p>An ancient practice of vaccination is leishmanization, in which intradermal inoculation of small amounts of virulent <italic toggle="yes">Leishmania</italic> (<italic toggle="yes">L</italic>.) <italic toggle="yes">major</italic> provides more than 90% protection against reinfection; this has been used in Israel, Iran, and the Soviet Union [<xref rid="B10-pathogens-11-00431" ref-type="bibr">10</xref>,<xref rid="B11-pathogens-11-00431" ref-type="bibr">11</xref>]. While leishmanization may potentially be an effective means of infection prophylaxis for some individuals, it is no longer practiced due to a range of safety and ethical reasons including non-healing skin lesions, exacerbation of skin diseases, the potential impact of immunosuppression, poor quality control, and the emergence of HIV, among others [<xref rid="B12-pathogens-11-00431" ref-type="bibr">12</xref>]. Scientific innovation and technological advances have paved the way for the development of efficient ways to generate an effective vaccine against leishmaniasis as an alternative to leishmanization. Although to this date there is no vaccine available against human leishmaniasis, a vaccine against different forms should, in theory, be possible [<xref rid="B13-pathogens-11-00431" ref-type="bibr">13</xref>]. Thus, over the years a multitude of vaccine strategies have been studied to control human leishmaniasis, which can be classified into first-generation vaccines (using dead parasites), second-generation vaccines (using genetically modified parasites expressing <italic toggle="yes">Leishmania</italic> genes encoding for recombinant proteins), and third-generation vaccines (plasmid-DNA based) [<xref rid="B14-pathogens-11-00431" ref-type="bibr">14</xref>]. For brevity, a discussion on all the experimental vaccines is not being attempted in this article.</p><sec id="sec2dot1-pathogens-11-00431"><title>2.1. First-Generation Vaccines</title><p>The first-generation vaccines composed of whole, killed parasites were used instead of leishmanization [<xref rid="B15-pathogens-11-00431" ref-type="bibr">15</xref>]. Several vaccination trials were conducted in many parts of the world using heat-killed whole <italic toggle="yes">Leishmania</italic> promastigotes as immunogens [<xref rid="B16-pathogens-11-00431" ref-type="bibr">16</xref>,<xref rid="B17-pathogens-11-00431" ref-type="bibr">17</xref>,<xref rid="B18-pathogens-11-00431" ref-type="bibr">18</xref>,<xref rid="B19-pathogens-11-00431" ref-type="bibr">19</xref>,<xref rid="B20-pathogens-11-00431" ref-type="bibr">20</xref>,<xref rid="B21-pathogens-11-00431" ref-type="bibr">21</xref>,<xref rid="B22-pathogens-11-00431" ref-type="bibr">22</xref>,<xref rid="B23-pathogens-11-00431" ref-type="bibr">23</xref>]. These vaccine candidates offer a huge repertoire of parasite antigens, and they can promote significant protection against infection [<xref rid="B24-pathogens-11-00431" ref-type="bibr">24</xref>,<xref rid="B25-pathogens-11-00431" ref-type="bibr">25</xref>,<xref rid="B26-pathogens-11-00431" ref-type="bibr">26</xref>,<xref rid="B27-pathogens-11-00431" ref-type="bibr">27</xref>]. Many studies exemplify the ability of a killed <italic toggle="yes">Leishmania</italic> vaccine adjuvanted with or without BCG to be a safe option [<xref rid="B22-pathogens-11-00431" ref-type="bibr">22</xref>,<xref rid="B28-pathogens-11-00431" ref-type="bibr">28</xref>,<xref rid="B29-pathogens-11-00431" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-11-00431" ref-type="bibr">30</xref>,<xref rid="B31-pathogens-11-00431" ref-type="bibr">31</xref>,<xref rid="B32-pathogens-11-00431" ref-type="bibr">32</xref>]. However, this type of vaccine-induced immunity is not sustained and wanes over time, which resulted in reduced efficacy in clinical trials [<xref rid="B15-pathogens-11-00431" ref-type="bibr">15</xref>,<xref rid="B26-pathogens-11-00431" ref-type="bibr">26</xref>,<xref rid="B29-pathogens-11-00431" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-11-00431" ref-type="bibr">30</xref>,<xref rid="B33-pathogens-11-00431" ref-type="bibr">33</xref>,<xref rid="B34-pathogens-11-00431" ref-type="bibr">34</xref>].</p></sec><sec id="sec2dot2-pathogens-11-00431"><title>2.2. Second-Generation Vaccines</title><p>While the first-generation vaccines are still undergoing evaluation, additional research has also focused on second-generation vaccines. This includes trials using different recombinant molecules and parasite antigens including purified native protein fractions, bacteria or viruses carrying and expressing leishmanial genes, or even synthetic peptides representing epitopes of antigen [<xref rid="B35-pathogens-11-00431" ref-type="bibr">35</xref>,<xref rid="B36-pathogens-11-00431" ref-type="bibr">36</xref>]. These numerous subunits and recombinant <italic toggle="yes">Leishmania</italic> vaccine candidates utilize distinguished <italic toggle="yes">Leishmania</italic> antigens, including gp63, p36/LACK, A-2, FML, PSA-2/gp46/M-2, LCR1, ORFF, KMP11, LeIF, LmSTI1, TSA, HASPB1, protein Q, cysteine protease B(CPB), and A (CPA), and have been extensively reviewed [<xref rid="B36-pathogens-11-00431" ref-type="bibr">36</xref>,<xref rid="B37-pathogens-11-00431" ref-type="bibr">37</xref>,<xref rid="B38-pathogens-11-00431" ref-type="bibr">38</xref>,<xref rid="B39-pathogens-11-00431" ref-type="bibr">39</xref>,<xref rid="B40-pathogens-11-00431" ref-type="bibr">40</xref>]. Studies with many of these recombinant antigen vaccines in pre-clinical experimental models have shown the stimulation of a protective immune response against reinfection during CL and VL [<xref rid="B38-pathogens-11-00431" ref-type="bibr">38</xref>,<xref rid="B40-pathogens-11-00431" ref-type="bibr">40</xref>]. Notably, recombinant antigen vaccines such as LEISH-F1, LIESH-F2 (against CL), and LEISH-F3 formulated in GLA-SE adjuvant (against <italic toggle="yes">L. donovani</italic> and <italic toggle="yes">L. infantum</italic>) have reached Phase II clinical trials with promising results [<xref rid="B41-pathogens-11-00431" ref-type="bibr">41</xref>,<xref rid="B42-pathogens-11-00431" ref-type="bibr">42</xref>,<xref rid="B43-pathogens-11-00431" ref-type="bibr">43</xref>,<xref rid="B44-pathogens-11-00431" ref-type="bibr">44</xref>,<xref rid="B45-pathogens-11-00431" ref-type="bibr">45</xref>]. There has been much activity in the discovery of second-generation vaccine candidates for leishmaniasis since they pose no risk of infection and are suitable for immunocompromised individuals; however, difficulty in the isolation of enough purified protein for a subunit vaccine is a drawback that could hinder their widespread utilization [<xref rid="B23-pathogens-11-00431" ref-type="bibr">23</xref>,<xref rid="B46-pathogens-11-00431" ref-type="bibr">46</xref>]. <italic toggle="yes">Leishmania</italic> parasites are transmitted to a host during the sand fly bite, along with sand fly saliva. However, when these vaccines were tested against needle challenge versus sand fly transmission of a virulent parasite, they were either partially protective or not protective against the latter [<xref rid="B47-pathogens-11-00431" ref-type="bibr">47</xref>,<xref rid="B48-pathogens-11-00431" ref-type="bibr">48</xref>,<xref rid="B49-pathogens-11-00431" ref-type="bibr">49</xref>,<xref rid="B50-pathogens-11-00431" ref-type="bibr">50</xref>]. Further, pre-exposure to sand fly saliva has been shown to confer protection against vector-transmitted leishmaniasis, which raised the possibility to use sand fly salivary proteins as potential vaccine candidates either alone or combined with <italic toggle="yes">Leishmania</italic> proteins and is currently an expanding area of vaccinology research [<xref rid="B51-pathogens-11-00431" ref-type="bibr">51</xref>,<xref rid="B52-pathogens-11-00431" ref-type="bibr">52</xref>,<xref rid="B53-pathogens-11-00431" ref-type="bibr">53</xref>]. Nevertheless, a recent clinical study reported that immunity to vector saliva is compromised by short sand fly seasons in endemic regions of Tbilisi, Georgia, with temperate climates [<xref rid="B54-pathogens-11-00431" ref-type="bibr">54</xref>]. </p></sec><sec id="sec2dot3-pathogens-11-00431"><title>2.3. Third-Generation Vaccines</title><p>Third-generation vaccines utilize the direct injection of nucleic acids, comprised of either naked plasmid DNA or DNA encapsulated in a viral vector. Vaccinations with DNA encoding gp63, LACK, and PSA-2 all protected both genetically resistant and susceptible mice from infection with <italic toggle="yes">L. major</italic> [<xref rid="B55-pathogens-11-00431" ref-type="bibr">55</xref>,<xref rid="B56-pathogens-11-00431" ref-type="bibr">56</xref>,<xref rid="B57-pathogens-11-00431" ref-type="bibr">57</xref>,<xref rid="B58-pathogens-11-00431" ref-type="bibr">58</xref>,<xref rid="B59-pathogens-11-00431" ref-type="bibr">59</xref>], albeit they were not found to be protective against <italic toggle="yes">L. chagasi</italic> infection in BALB/C mice or against experimental VL [<xref rid="B60-pathogens-11-00431" ref-type="bibr">60</xref>,<xref rid="B61-pathogens-11-00431" ref-type="bibr">61</xref>]. Additional DNA vaccine candidates include genes encoding for proteins such as TSA, KMP11, A-2, NH36, LmSTI1, cysteine proteases, and histones have been shown to induce protective immunity in animal models and were previously reviewed [<xref rid="B62-pathogens-11-00431" ref-type="bibr">62</xref>]. In some studies, to improve the efficacy of DNA vaccines, the priming of these vaccines was accompanied by boosting the corresponding protein expressed on a recombinant viral vector such as vaccinia virus (VV) or modified vaccinia virus Ankara (MVA) [<xref rid="B63-pathogens-11-00431" ref-type="bibr">63</xref>,<xref rid="B64-pathogens-11-00431" ref-type="bibr">64</xref>,<xref rid="B65-pathogens-11-00431" ref-type="bibr">65</xref>,<xref rid="B66-pathogens-11-00431" ref-type="bibr">66</xref>]. A very recent Phase I clinical trial in 20 healthy volunteers reported that a Simian adenovirus (ChAd63) constituted of KMP-11 and HASPB, two genes of <italic toggle="yes">L. donovani,</italic> could effectively elicit a wide range of CD8+ T cells specific for <italic toggle="yes">Leishmania</italic> antigens and act as a promising approach for the prevention and treatment of human VL and post-kala-azar dermal leishmaniasis [<xref rid="B67-pathogens-11-00431" ref-type="bibr">67</xref>]. Importantly, the therapeutic effects of ChAd63-KH in Phase II of a non-randomized clinical trial are currently being evaluated [<xref rid="B68-pathogens-11-00431" ref-type="bibr">68</xref>]. Collectively, DNA vaccines in animal models are successful because they are stable, do not require adjuvants, produce the antigen over long periods, and can easily be produced in large quantities. [<xref rid="B62-pathogens-11-00431" ref-type="bibr">62</xref>]. However, concerns raised in relation to safety, such as the integration of the DNA into the mammalian genome and the induction of autoimmune diseases or cancer, have impeded the development of DNA-based vaccines for leishmaniasis [<xref rid="B69-pathogens-11-00431" ref-type="bibr">69</xref>]. </p></sec><sec id="sec2dot4-pathogens-11-00431"><title>2.4. Live Attenuated Vaccines</title><p>Live attenuated vaccines involve genetic modification of a parasite&#8217;s genes responsible for its virulence and/or survival and are of current interest in <italic toggle="yes">Leishmania</italic> vaccine research. It is an appealing approach because they closely mimic natural infection, ensuring the induction of immune responses consistent with protection without the danger associated with infection with live virulent parasites [<xref rid="B70-pathogens-11-00431" ref-type="bibr">70</xref>]. Early live attenuated <italic toggle="yes">Leishmania</italic> parasites developed through targeted deletion exhibited promise in inducing strong protection against homologous and heterologous challenge [<xref rid="B71-pathogens-11-00431" ref-type="bibr">71</xref>]. Because of the comparative ease of <italic toggle="yes">Leishmania</italic> whole-genome sequencing, along with the consequent capacity to monitor genome stability, there are fewer obstacles hindering testing genetically attenuated <italic toggle="yes">Leishmania</italic> parasites as candidate vaccines [<xref rid="B72-pathogens-11-00431" ref-type="bibr">72</xref>]. Numerous targeted gene deletions have been carried out recently to develop <italic toggle="yes">Leishmania</italic> live attenuated vaccine strains from <italic toggle="yes">L. major</italic>, <italic toggle="yes">L. mexicana</italic>, <italic toggle="yes">L. amazonensis</italic>, and <italic toggle="yes">L. donovani</italic>, which demonstrated significant protection against CL and VL in susceptible mice [<xref rid="B73-pathogens-11-00431" ref-type="bibr">73</xref>,<xref rid="B74-pathogens-11-00431" ref-type="bibr">74</xref>,<xref rid="B75-pathogens-11-00431" ref-type="bibr">75</xref>,<xref rid="B76-pathogens-11-00431" ref-type="bibr">76</xref>,<xref rid="B77-pathogens-11-00431" ref-type="bibr">77</xref>]. Notably, experimental mouse immunization with <italic toggle="yes">Biopterin transporter 1</italic> (<italic toggle="yes">BT1</italic>)-deleted <italic toggle="yes">L. donovani</italic> parasites [<xref rid="B78-pathogens-11-00431" ref-type="bibr">78</xref>] and <italic toggle="yes">A2&#8211;rel</italic> gene cluster in <italic toggle="yes">L. donovani</italic> [<xref rid="B79-pathogens-11-00431" ref-type="bibr">79</xref>] as well as <italic toggle="yes">SIR2</italic> [<xref rid="B80-pathogens-11-00431" ref-type="bibr">80</xref>], <italic toggle="yes">Hsp70-II</italic> [<xref rid="B81-pathogens-11-00431" ref-type="bibr">81</xref>], and <italic toggle="yes">KHARON1</italic> (KH1) <italic toggle="yes">L. infantum</italic> null mutants [<xref rid="B82-pathogens-11-00431" ref-type="bibr">82</xref>] as immunogens elicited protection against virulent challenge in BALB/c mice. Another <italic toggle="yes">L. donovani</italic> mutant attenuated for the p27 gene (<italic toggle="yes">Ldp27<sup>-/-</sup></italic>), encoding an amastigote-specific cytochrome <italic toggle="yes">c</italic> oxidase component, resulted in reduced parasitic loads and long-lasting protection against CL and VL challenge [<xref rid="B83-pathogens-11-00431" ref-type="bibr">83</xref>,<xref rid="B84-pathogens-11-00431" ref-type="bibr">84</xref>]. Studies with several other defined attenuated <italic toggle="yes">Leishmania</italic> vaccines with specific gene targets such as <italic toggle="yes">dhfr</italic>, <italic toggle="yes">lpg2</italic>, <italic toggle="yes">cpa</italic>, <italic toggle="yes">cpb</italic>, <italic toggle="yes">Ufm1</italic>, and the paraflagellar rod-2 locus have shown differential protection in animal models [<xref rid="B15-pathogens-11-00431" ref-type="bibr">15</xref>,<xref rid="B85-pathogens-11-00431" ref-type="bibr">85</xref>,<xref rid="B86-pathogens-11-00431" ref-type="bibr">86</xref>]. For example, <italic toggle="yes">dhfr-ts</italic> null mutants of <italic toggle="yes">L. major</italic> could elicit significant resistance after BALB/c mice challenge with virulent <italic toggle="yes">L. major</italic> [<xref rid="B87-pathogens-11-00431" ref-type="bibr">87</xref>], while they were unable to induce protective immunity in primates [<xref rid="B88-pathogens-11-00431" ref-type="bibr">88</xref>]. <italic toggle="yes">L. mexicana</italic> mutants lacking cysteine proteinase genes resulted in delayed disease onset, smaller lesions, and lower parasite burden in mice and hamsters [<xref rid="B89-pathogens-11-00431" ref-type="bibr">89</xref>,<xref rid="B90-pathogens-11-00431" ref-type="bibr">90</xref>]. Similarly, phosphoglycan-deficient <italic toggle="yes">L. major</italic> immunization protected highly susceptible mice against virulent challenge without eliciting a strong Th1 response [<xref rid="B91-pathogens-11-00431" ref-type="bibr">91</xref>]. Summarizing numerous experimental evidence, Rivier et al. [<xref rid="B92-pathogens-11-00431" ref-type="bibr">92</xref>] concluded that injection of attenuated parasites achieved more heightened protection than any other method involving recombinant gp63 as a test antigen delivered with a variety of adjuvants and delivery systems. Collectively, it is interesting that similar gene-cloning technology that allowed the isolation of genes encoding vaccine candidates can now be used for engineering the ablation of essential genes in <italic toggle="yes">Leishmania</italic>, thus making the use of live attenuated vaccines a much more attractive proposition than ever before [<xref rid="B93-pathogens-11-00431" ref-type="bibr">93</xref>]. </p><p>The use of live attenuated mutants as a prophylactic vaccine strategy is not an approach unique to leishmaniasis, but it has been successfully used for inducing protection against other parasitic diseases, such as malaria [<xref rid="B94-pathogens-11-00431" ref-type="bibr">94</xref>,<xref rid="B95-pathogens-11-00431" ref-type="bibr">95</xref>,<xref rid="B96-pathogens-11-00431" ref-type="bibr">96</xref>,<xref rid="B97-pathogens-11-00431" ref-type="bibr">97</xref>]. Live attenuated parasites lead to strong, long-lasting protection and could be utilized as a generalized strategy for all parasitic agents. </p><p>Our laboratory has developed live attenuated <italic toggle="yes">Leishmania</italic> vaccines by targeted <italic toggle="yes">centrin</italic> gene disruptions, the sequential history of which will be elaborated in the following sections.</p></sec></sec><sec id="sec3-pathogens-11-00431"><title>3. <italic toggle="yes">Leishmania centrin</italic> Knockout Parasites as a Vaccine Strategy against Leishmaniasis</title><sec id="sec3dot1-pathogens-11-00431"><title>3.1. Centrin-1-Deficient Leishmania donovani</title><p><italic toggle="yes">Leishmania centrin</italic> is a calcium-binding protein located in the basal body of the parasite that regulates duplication or segregation of the centrosome. Specifically, <italic toggle="yes">Leishmania</italic> encodes five different <italic toggle="yes">centrin</italic> genes. Our group previously identified that one of them, the <italic toggle="yes">Leishmania centrin</italic> gene-1, is necessary for the growth and differentiation of the parasite, and its expression increases with differentiation from the promastigote to the amastigote stages [<xref rid="B98-pathogens-11-00431" ref-type="bibr">98</xref>]. Because of the role of <italic toggle="yes">centrin</italic> in sustaining parasite proliferation, it became an interesting target for deletion to generate a live attenuated <italic toggle="yes">Leishmania</italic> mutant with the potential to be used as a vaccine [<xref rid="B98-pathogens-11-00431" ref-type="bibr">98</xref>]. Hence, in 2004, our group developed a <italic toggle="yes">centrin</italic> null mutant of <italic toggle="yes">Leishmania donovani</italic> (<italic toggle="yes">LdCen<sup>-/-</sup></italic>) by replacing the <italic toggle="yes">centrin</italic> gene with antibiotic-resistant genes. Microscopic analysis revealed a similar morphology between <italic toggle="yes">LdCen<sup>-/-</sup></italic> and wild-type (WT) <italic toggle="yes">L. donovani</italic> promastigotes. Nevertheless, the story was much different in the amastigote stage, where centrin deficiency resulted in the lack of basal bodies&#8217; formation and cytokinesis, which led to the induction of apoptosis and cell arrest at the G2/M phase. This inhibited amastigote growth also in in vivo infected macrophages [<xref rid="B99-pathogens-11-00431" ref-type="bibr">99</xref>]. It seems that, even when <italic toggle="yes">LdCen<sup>-/-</sup></italic> can undergo kinetoplast and nuclear division, these parasites are incapable of complete cell division in the amastigote, forming large, multi-nucleated cells, resulting in apoptotic death of the parasite that can be easily cleared by the immune system [<xref rid="B98-pathogens-11-00431" ref-type="bibr">98</xref>,<xref rid="B99-pathogens-11-00431" ref-type="bibr">99</xref>]. Importantly, despite its major effects on amastigote replication, a lack of <italic toggle="yes">centrin</italic> does not affect promastigote replication in culture. Therefore, a live attenuated vaccine can be cultured even in high quantities, highlighting the relevance of these mutants in vaccine development [<xref rid="B100-pathogens-11-00431" ref-type="bibr">100</xref>]. </p><p>In rodent studies, immunization with <italic toggle="yes">LdCen<sup>-/-</sup></italic> generated long-lasting protection against the challenge with two WT <italic toggle="yes">Leishmania</italic> strains, <italic toggle="yes">L. donovani</italic> and <italic toggle="yes">L. braziliensis</italic>, causative agents of visceral and mucocutaneous leishmaniasis, respectively (<xref rid="pathogens-11-00431-f001" ref-type="fig">Figure 1</xref>). Protection was demonstrated by the reduction in parasitic burden in the spleen and liver in comparison with non-vaccinated mice [<xref rid="B101-pathogens-11-00431" ref-type="bibr">101</xref>]. Moreover, <italic toggle="yes">LdCen<sup>-/-</sup></italic> provides protection against <italic toggle="yes">L. mexicana</italic>, an American <italic toggle="yes">Leishmania</italic> strain causative of CL, observed by the lack of dermal lesion characteristic in non-immunized mice. Immunized mice showed a strong influx of MHC-II-expressing macrophages towards the <italic toggle="yes">L. mexicana</italic> challenge site, an increased number of IFN-&#947;-producing cells, and a reduction in IL-4 and IL-13 production, altogether characteristic of a protective inflammatory immune profile (<xref rid="pathogens-11-00431-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B83-pathogens-11-00431" ref-type="bibr">83</xref>]. It is important to highlight that <italic toggle="yes">LdCen<sup>-/-</sup></italic> seems to provide a broad range of antigens that allow cross protection against different strains of <italic toggle="yes">Leishmania</italic>, including species endemic from different regions and causative of different manifestations of <italic toggle="yes">Leishmaniasis</italic>.</p><p>Moreover, <italic toggle="yes">LdCen<sup>-/-</sup></italic> vaccine was demonstrated to be safe and effective even in immunosuppressed mice. This protection was correlated with an increase in both Th17 and Th1 immune responses [<xref rid="B101-pathogens-11-00431" ref-type="bibr">101</xref>,<xref rid="B102-pathogens-11-00431" ref-type="bibr">102</xref>]. CD4+ and CD8+ cells produced IL-1&#946;, IL-6, TGF-&#946;, and IL-23, cytokines necessary to sustain IL-17 production [<xref rid="B102-pathogens-11-00431" ref-type="bibr">102</xref>]. Additionally, there was an increase in Th1 cells, cytotoxic CD8+ T cells, and a higher ratio of IFN-&#947;/IL-10-producing T cells, as well as higher IgG levels, particularly of Th1-promoting IgG2a [<xref rid="B101-pathogens-11-00431" ref-type="bibr">101</xref>]. This is explained by the downregulation of the CD200-CD200R axis, an immune inhibitory pathway that is activated during WT <italic toggle="yes">L. donovani</italic> infection. However, infection with <italic toggle="yes">LdCen<sup>-/-</sup></italic> limits the expression of CD200 in CD11c+ dendritic cells, resulting in the reduction in IL-10 and the increase in IFN-&#947; and TNF-&#945; production by CD4+ T cells [<xref rid="B103-pathogens-11-00431" ref-type="bibr">103</xref>]. This potential live attenuated vaccine is effective even in aged mice, where protection against WT <italic toggle="yes">L. donovani</italic> was also provided, with similar, though less strong, immune response compared to young mice [<xref rid="B104-pathogens-11-00431" ref-type="bibr">104</xref>]. </p><p>The adaptive immune response is favored and triggered by the innate immune response, particularly by macrophages, which are also the final host for <italic toggle="yes">Leishmania</italic> [<xref rid="B105-pathogens-11-00431" ref-type="bibr">105</xref>,<xref rid="B106-pathogens-11-00431" ref-type="bibr">106</xref>]. In order to favor its own survival, <italic toggle="yes">Leishmania</italic> modulates the immune response, usually by downregulating inflammatory pathways, leading to M1 polarization and, consequently, to Th1 activation [<xref rid="B106-pathogens-11-00431" ref-type="bibr">106</xref>,<xref rid="B107-pathogens-11-00431" ref-type="bibr">107</xref>]. Therefore, the polarization of macrophages after <italic toggle="yes">LdCen<sup>-/-</sup></italic> vaccination is a determinant of protection. In vitro and in vivo models of infection showed that <italic toggle="yes">LdCen<sup>-/-</sup></italic> parasites induce classical activation of macrophages towards an M1 phenotype. The M1 response was higher during <italic toggle="yes">LdCen<sup>-/-</sup></italic> infection, compared to WT <italic toggle="yes">L. donovani infection</italic>, and was characterized by the upregulation of inflammatory mediator transcripts (IL-1&#946;, IL-12, TNF-&#945;, and iNOS2) and the downregulation of M2-related genes (<italic toggle="yes">IL-10</italic>, <italic toggle="yes">YM1</italic>, <italic toggle="yes">Arg-1</italic>, and <italic toggle="yes">MRC-1</italic> genes). Unlike WT parasites, <italic toggle="yes">LdCen<sup>-/-</sup></italic> does not dampen the effector functions of macrophages and allows for the establishment of an M1 phenotype, which favors the anti-parasitic response by activating a protective adaptive immunity [<xref rid="B108-pathogens-11-00431" ref-type="bibr">108</xref>]. Additionally, it was recently reported by our group that <italic toggle="yes">LdCen<sup>-/-</sup></italic> immunization results in a stronger recruitment of neutrophils to the infection site, mediated by CCL2 and CCL3, compared to its WT homologous strain [<xref rid="B109-pathogens-11-00431" ref-type="bibr">109</xref>]. This is not only important because neutrophils are the first responders against <italic toggle="yes">Leishmania</italic> infection [<xref rid="B110-pathogens-11-00431" ref-type="bibr">110</xref>] but also because the efficacy of <italic toggle="yes">LdCen<sup>-/-</sup></italic> seems to be dependent on these cells. Particularly, we identified two distinct neutrophil subtypes, N&#945; and N&#946;, where N&#945; could induce the ex vivo proliferation of T cells. This last population was observed in higher numbers after immunization with <italic toggle="yes">LdCen<sup>-/-</sup>,</italic> compared to infection with WT <italic toggle="yes">L. donovani</italic> [<xref rid="B109-pathogens-11-00431" ref-type="bibr">109</xref>]. Therefore, these results demonstrate that <italic toggle="yes">LdCen<sup>-/-</sup></italic> induces strong innate immune responses, which are favorable for T cell anti-parasitic activity. </p></sec><sec id="sec3dot2-pathogens-11-00431"><title>3.2. L. donovani Cen<sup>-/-</sup> for the Vaccination of Reservoirs of the Infection</title><p>Vaccination would not only prevent infected patients from developing severe forms of VL but can also protect infected asymptomatic individuals who do not receive drug treatment due to the lack of clinical evidence of infection. Asymptomatic individuals are considered to be reservoirs for the parasite and allow the continuous transmission of the disease. Therefore, vaccination would prevent new infections and, eventually, eradicate the disease [<xref rid="B111-pathogens-11-00431" ref-type="bibr">111</xref>]. Because asymptomatic infections are significantly more frequent than symptomatic cases, and asymptomatic individuals would likely be the predominant population receiving the vaccine, we considered that testing the live attenuated <italic toggle="yes">LdCen<sup>-/-</sup></italic> vaccine in asymptomatic individuals would be of epidemiological relevance. Mice infected with WT <italic toggle="yes">L. donovani</italic> were used as a model for asymptomatic infection as they resembled the immunological conditions of asymptomatic individuals with high percentages of IFN-&#947;-producing cells and fewer IL-10-producing cells, as well as low parasitic burdens, characteristic of host protection. The central memory response was shown to be very similar after vaccination among asymptomatic mice and na&#239;ve mice, showing that <italic toggle="yes">LdCen<sup>-/-</sup></italic> is immunogenic also in asymptomatic individuals. Moreover, these mutants generate protection against WT <italic toggle="yes">L. donovani</italic> challenge in asymptomatic mice, similarly to na&#239;ve mice vaccinated with <italic toggle="yes">LdCen<sup>-/-</sup></italic>. Hence, this live attenuated vaccine could also be used to target asymptomatic individuals in endemic regions [<xref rid="B112-pathogens-11-00431" ref-type="bibr">112</xref>]. </p><p>Months after VL clinical cure is diagnosed, some VL patients can develop a dermal manifestation of leishmaniasis called post-kala-azar dermal leishmaniasis (PKDL). PKDL occurs in 5&#8211;15% in the Indian subcontinent and up to 50% in Sudan of the patients apparently cured of VL [<xref rid="B113-pathogens-11-00431" ref-type="bibr">113</xref>]. Individuals with PKDL are considered an important reservoir as they can sustain anthroponotic transmission of <italic toggle="yes">Leishmania</italic>; therefore, targeting those individuals is considered necessary for the VL elimination program [<xref rid="B114-pathogens-11-00431" ref-type="bibr">114</xref>]. Therefore, <italic toggle="yes">LdCen<sup>-/-</sup></italic> was tested in human cells of patients with healed VL and PKDL. After stimulation with <italic toggle="yes">LdCen<sup>-/-</sup></italic>, macrophages obtained from PMBCs showed a strong production of IFN-&#947;, TNF-&#945;, IL-2, IL-6, IL-12, and IL-17 and an increase in the percentage of IFN-&#947;-producing T cells (both CD4+ and CD8+) [<xref rid="B115-pathogens-11-00431" ref-type="bibr">115</xref>], hence demonstrating that <italic toggle="yes">LdCen<sup>-/-</sup></italic> generates a protective Th1 immune response in humans, particularly in PKDL and healed individuals. </p><p>Furthermore, the <italic toggle="yes">LdCen<sup>-/-</sup></italic> vaccine has been tested in dogs, which are also an important reservoir for <italic toggle="yes">L. infantum</italic> in endemic regions. Dog vaccination is a necessary approach, as treating them generates drug resistance to the same drugs administered to humans. Currently, the recombinant vaccine Leishmune<sup>&#174;</sup> is commercially available for canine use. When <italic toggle="yes">LdCen<sup>-/-</sup></italic> immunogenicity was compared to Leishmune<sup>&#174;</sup> in a canine model, a similar anti-<italic toggle="yes">L. infantum</italic> antibody response was observed, in both cases higher than in unvaccinated dogs. On the other hand, T cell responses were stronger in dogs vaccinated with <italic toggle="yes">LdCen<sup>-/-</sup>,</italic> specifically CD4+ and CD8+ T cell proliferation, CD8+ T cell activation, IFN-&#947; production, a general decrease in IL-4 production, and an increase in TNF-&#945; and IL-12/IL-23p40 secretion by T cells. Therefore, the <italic toggle="yes">LdCen<sup>-/-</sup></italic> vaccine is also immunogenic in dogs and it could also be used for preventing reservoir generation [<xref rid="B116-pathogens-11-00431" ref-type="bibr">116</xref>]. More importantly, <italic toggle="yes">LdCen<sup>-/-</sup></italic> provided a long-term protection (24 months) against <italic toggle="yes">L. infantum</italic> in dogs and a reduction in parasitic burden in the bone marrow [<xref rid="B117-pathogens-11-00431" ref-type="bibr">117</xref>]. Although protection and antibody response were very similar to dogs vaccinated with Leishmune<sup>&#174;</sup>, those vaccinated with <italic toggle="yes">LdCen<sup>-/-</sup></italic> showed enhanced CD8+ T cell proliferation, a stronger Th1 response, and reduced IL-4 secretion [<xref rid="B117-pathogens-11-00431" ref-type="bibr">117</xref>,<xref rid="B118-pathogens-11-00431" ref-type="bibr">118</xref>]. Therefore, <italic toggle="yes">LdCen<sup>-/-</sup></italic> could efficiently help control <italic toggle="yes">L. infantum</italic> transmission by dogs. </p></sec><sec id="sec3dot3-pathogens-11-00431"><title>3.3. L. major Cen<sup>-/-</sup> as a Safer Alternative to L. donovani Cen<sup>-/-</sup> and Leishmanization</title><p>Despite the high vaccine efficacy with <italic toggle="yes">LdCen<sup>-/-</sup></italic>, several concerns remain, preventing the advancement of this mutant to human clinical trials. First of all, <italic toggle="yes">LdCen<sup>-/-</sup></italic> parasites contain an antibiotic-resistance gene integrated in their genome [<xref rid="B100-pathogens-11-00431" ref-type="bibr">100</xref>]. In order to improve safety, a more efficient genetic engineering technique that does not require the insertion of antibiotic resistance, such as CRISPR-Cas9, had to be employed. Additionally, <italic toggle="yes">L. donovani</italic> WT is known to disseminate to the spleen and liver and cause visceral disease [<xref rid="B119-pathogens-11-00431" ref-type="bibr">119</xref>]. Due to its visceral nature and lack of visible clinical symptoms such as cutaneous lesions, VL often requires invasive procedures such as splenic and bone marrow aspirates in order to be diagnosed [<xref rid="B120-pathogens-11-00431" ref-type="bibr">120</xref>]. Once the disease is established, 95% of VL cases result in death when left untreated. Furthermore, the therapeutics available for VL often present toxicity and other side effects [<xref rid="B119-pathogens-11-00431" ref-type="bibr">119</xref>]. Because of these issues, the risks associated with the potential visceralization of <italic toggle="yes">LdCen<sup>-/-</sup></italic> parasites prevent these mutants from being able to advance to clinical trials. Therefore, the use of a non-visceralizing, dermotropic <italic toggle="yes">Leishmania</italic> strain can improve safety. <italic toggle="yes">L. major</italic> is a particularly promising candidate as it is dermotropic and its infection presents with mild symptoms and a self-healing disease, compared to other cutaneous strains [<xref rid="B121-pathogens-11-00431" ref-type="bibr">121</xref>]. Furthermore, <italic toggle="yes">L. major</italic> has already been shown to effectively prevent subsequent infection through the practice of Leishmanization [<xref rid="B11-pathogens-11-00431" ref-type="bibr">11</xref>].</p></sec><sec id="sec3dot4-pathogens-11-00431"><title>3.4. L. major Cen<sup>-/-</sup> Mutants Provide Safe and Long-Term Immunity</title><p>Recently, our group developed a genetically engineered <italic toggle="yes">L. major centrin</italic> (<italic toggle="yes">LmCen<sup>-/-</sup></italic>) gene knockout mutant strain using the CRISPR-Cas9 technique [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. This technique allows for the targeted deletion of the <italic toggle="yes">centrin</italic> gene without the insertion of an antibiotic-resistance marker into the <italic toggle="yes">Leishmania</italic> genome, which is important for advancement to Phase I human clinical trials. These parasites are safe even in susceptible and immunocompromised mouse models, where <italic toggle="yes">LmCen<sup>-/-</sup></italic> infection does not cause the development of lesions [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. </p><p>Immunization with <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites elicited protection against intradermal needle challenge with virulent <italic toggle="yes">L. major</italic> [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. Murine models physiologically relevant to human infection, such as the challenge with intradermal needle injection and sand fly challenge, are dependable approaches that simulate what would happen in endemic areas after vaccination. In particular, sand fly challenge mimics the natural route of infection and has been shown to modify the immune response to infection and vaccination. A previous study in particular showed that a killed <italic toggle="yes">L. major</italic> vaccine was able to protect against needle but not sand fly challenge; this was due to a population of neutrophils hindering vaccine efficacy [<xref rid="B47-pathogens-11-00431" ref-type="bibr">47</xref>]. Interestingly, <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants also conferred protection against sand fly challenge [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>], which has not been previously demonstrated in other <italic toggle="yes">Leishmania</italic> vaccine studies [<xref rid="B47-pathogens-11-00431" ref-type="bibr">47</xref>,<xref rid="B48-pathogens-11-00431" ref-type="bibr">48</xref>,<xref rid="B49-pathogens-11-00431" ref-type="bibr">49</xref>,<xref rid="B50-pathogens-11-00431" ref-type="bibr">50</xref>]. This protection was mediated by the rapid recruitment of multifunctional effector cells at the infection site, initiating a fast immune response after challenge [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. Protection against sand fly challenge is a fundamental benefit for the advancement of these mutants to clinical trials as it is physiologically relevant to natural human infection.</p><p>Overall, immunization with <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites was comparable to Leishmanization in conferring protection against needle or sand fly challenge with virulent <italic toggle="yes">L. major</italic> [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. In particular, mice immunized with <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites or healed from <italic toggle="yes">L. major</italic> WT (Leishmanization model) generated a comparable significantly higher pro-inflammatory immune response, characterized by IFN-&#947;+ effector T cells (Live CD4+CD44<sup>Hi</sup>Ly6C+T-bet+) and tissue resident memory (TRM) T cell response compared to the non-immunized challenged group (<xref rid="pathogens-11-00431-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. Taken all together, these results show that <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants represent an equally effective but safer alternative to <italic toggle="yes">L. donovani cen<sup>-/-</sup></italic> and Leishmanization for the protection against <italic toggle="yes">L. major</italic> WT needle and sand fly challenge.</p><p>Even though CL is the most common form of the disease, VL represents a much higher threat due to its potential to become fatal. Therefore, it is imperative that a vaccine against <italic toggle="yes">Leishmania</italic> is efficacious to prevent both cutaneous and visceral diseases. Recently, <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants were shown to be safe in a hamster immunocompromised model, while in immunocompetent hamsters immunization was efficacious for the long-term protection against sand fly challenge with virulent <italic toggle="yes">L. donovani</italic> [<xref rid="B122-pathogens-11-00431" ref-type="bibr">122</xref>]. Immunized and challenged hamsters presented a pro-inflammatory profile characterized by significantly higher spleen expression of IFN-&#947; and TNF-&#945; compared to non-immunized challenged hamsters (<xref rid="pathogens-11-00431-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B122-pathogens-11-00431" ref-type="bibr">122</xref>]. Furthermore, hamsters immunized with <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites showed enhanced Th1 responses and decreased Th2 responses in the spleen compared to the group infected with <italic toggle="yes">L. major</italic> WT (<xref rid="pathogens-11-00431-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B122-pathogens-11-00431" ref-type="bibr">122</xref>]. Taken all together, these results revealed that <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants are safe and effective vaccine candidates for pre-clinical models of CL and VL. However, the advancement of <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants to clinical trials requires these parasites to be grown under current Good Manufacturing Practices (cGMP). Our group recently demonstrated that Good Laboratory Practices (GLP)-grade <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites passed quality control and conferred long-term protection against <italic toggle="yes">L. donovani</italic> needle and sand fly challenges in hamsters [<xref rid="B122-pathogens-11-00431" ref-type="bibr">122</xref>]. These results were comparable to laboratory-grade <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants. Furthermore, GLP-grade <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites elicited the production of pro-inflammatory cytokines in human PBMCs [<xref rid="B122-pathogens-11-00431" ref-type="bibr">122</xref>], highlighting once more the potential of these parasites to serve as a candidate vaccine for human leishmaniasis.</p></sec><sec id="sec3dot5-pathogens-11-00431"><title>3.5. Towards Developing a Pan-Leishmania Vaccine</title><p>Towards the goal of generating a pan-<italic toggle="yes">Leishmania</italic> vaccine, the efficacy of <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites against challenge with other strains of <italic toggle="yes">Leishmania</italic> remains to be tested. Promising experimental data from <italic toggle="yes">L. donovani</italic> suggest cross protection among species. We hope to repeat these results using <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants. Furthermore, along with <italic toggle="yes">LmCen<sup>-/-</sup></italic> parasites, our group generated <italic toggle="yes">L. mexicana</italic> (a New World CL strain) <italic toggle="yes">Cen<sup>-/-</sup></italic> mutants and tested them against homologous and heterologous challenges in mice [<xref rid="B123-pathogens-11-00431" ref-type="bibr">123</xref>] and hamsters (unpublished data). We found growth defect in <italic toggle="yes">Cen<sup>-/-</sup> L. mexicana</italic> (<italic toggle="yes">LmexCen<sup>-/-</sup></italic>) amastigotes analogous to what was previously observed with <italic toggle="yes">L. major</italic> and <italic toggle="yes">L. donovani centrin</italic>-deleted mutants. <italic toggle="yes">LmexCen<sup>-/-</sup> parasites</italic> were also safe in immunocompromised mouse models and efficacious for the protection against <italic toggle="yes">L. mexicana</italic> wild-type parasite infection in genetically different BALB/c and C57BL/6 mice. Interestingly, while immunized BALB/c mice showed a decreased induction of Th2 responses, in C57BL/6 we observed increased Th1 responses in the skin and draining lymph nodes, suggesting a differential mechanism of protection depending on the host genetic background (<xref rid="pathogens-11-00431-f002" ref-type="fig">Figure 2</xref>). Nevertheless, <italic toggle="yes">LmexCen<sup>-/-</sup></italic> parasites showed long-lasting protection against homologous challenge with virulent <italic toggle="yes">L. mexicana</italic> by promoting pro-inflammatory immune responses and the generation of central T memory cells [<xref rid="B123-pathogens-11-00431" ref-type="bibr">123</xref>]. Immunization with the <italic toggle="yes">LmexCen<sup>-/-</sup></italic> parasites also induced robust host protection in hamsters against <italic toggle="yes">L. donovani</italic> infection transmitted by sand fly bites (unpublished data). A <italic toggle="yes">centrin</italic> deletion mutant in <italic toggle="yes">L. braziliensis</italic> background was developed by another group recently using CRISPR/Cas9. Similar to <italic toggle="yes">LdCen<sup>-/-</sup></italic>, <italic toggle="yes">LmCen<sup>-/-</sup></italic>, and <italic toggle="yes">LmexCen<sup>-/-</sup></italic> parasites, <italic toggle="yes">LbCen<sup>-/-</sup></italic> mutants also exhibited a growth defect in the amastigote stage and did not cause cutaneous lesions in BALB/c mice. <italic toggle="yes">LbCen<sup>-/-</sup></italic> parasites were undetectable in the ear, spleen, and lymph nodes by 6 weeks post-infection. Immunogenicity and protective efficacy characteristics of <italic toggle="yes">LbCen<sup>-/-</sup></italic> parasites against virulent challenge remain to be determined [<xref rid="B124-pathogens-11-00431" ref-type="bibr">124</xref>]. Overall, <italic toggle="yes">Cen<sup>-/-</sup></italic> parasites have shown promise as candidate vaccines against leishmaniasis; <italic toggle="yes">LmCen<sup>-/-</sup></italic> mutants in particular are being advanced to human Phase I clinical trials.</p></sec></sec><sec id="sec4-pathogens-11-00431"><title>4. Perspective</title><p>Several different vaccines against Leishmaniasis are currently being evaluated including newer RNA vaccines [<xref rid="B125-pathogens-11-00431" ref-type="bibr">125</xref>]. Beyond the demonstration of safety and efficacy characteristics in preclinical models, there is a new emphasis on identifying product development strategies towards the realization of a <italic toggle="yes">Leishmania</italic> vaccine. As some of the experimental vaccines enter large-scale production in the near future, cGMP manufacturing of <italic toggle="yes">L. major</italic> isolates in support of a Control Human Infection Model (CHIM) trial provided a framework to deploy manufacturing processes that are compliant with the expected regulatory standards [<xref rid="B126-pathogens-11-00431" ref-type="bibr">126</xref>]. In the absence of market incentives, the need for making a persuasive case in support of a <italic toggle="yes">Leishmania</italic> vaccine is being recognized. Due to the fluctuating nature of the case load of VL, Phase III trials to demonstrate the efficacy parameters may require creative strategies with respect to identifying and employing surrogate markers of efficacy since traditional measures of efficacy may be expensive and hard to realize. While CHIM studies make eminent sense for CL, currently there is no substantive equivalent for vaccine trials in VL as the parasites causing VL show a systemic dissemination and present a higher risk. However, CHIM studies have been used in <italic toggle="yes">P. falciparum</italic> malaria that also results in a systemic infection [<xref rid="B127-pathogens-11-00431" ref-type="bibr">127</xref>]. </p><p>The efficacy observed in rodent models immunized with <italic toggle="yes">LmCen<sup>-/-</sup></italic> that showed protection upon sandfly-mediated challenge with both <italic toggle="yes">L. major</italic> and <italic toggle="yes">L. donovani</italic> suggests that these mutants could be used as a pan-<italic toggle="yes">Leishmania</italic> vaccine [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>,<xref rid="B122-pathogens-11-00431" ref-type="bibr">122</xref>]. Immunization with <italic toggle="yes">LmCen<sup>-/-</sup></italic> has been shown to induce CD4+ T effector and tissue resident memory (TRM) T cell populations in frequencies comparable to leishmanization [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>,<xref rid="B128-pathogens-11-00431" ref-type="bibr">128</xref>]. The data from leishmanization studies suggests that a certain level of parasitic persistence might be essential to maintain long-lasting protective immunity. Interestingly, BALB/c mice immunized with <italic toggle="yes">LmCen<sup>-/-</sup></italic> and treated with dexamethasone showed some parasitic persistence at 15 weeks post-immunization [<xref rid="B8-pathogens-11-00431" ref-type="bibr">8</xref>]. A similar, low-level persistence was also found in STAT1 and STAT4 knockout mice immunized with <italic toggle="yes">LmexCen<sup>-/-</sup></italic> [<xref rid="B123-pathogens-11-00431" ref-type="bibr">123</xref>]. Therefore, parasitic persistence at low frequency observed in our studies might be needed to mediate long-term protection, in addition to the memory cell populations [<xref rid="B129-pathogens-11-00431" ref-type="bibr">129</xref>]. These results suggest that immunization with <italic toggle="yes">LmCen<sup>-/-</sup></italic> is a safer alternative to leishmanization with comparable protection and sharing a common immune mechanism of protection. A <italic toggle="yes">Leishmania</italic> skin test (LST) that measures the DTH response in a <italic toggle="yes">Leishmania</italic>-exposed individual may fulfill the need to measure the vaccine-induced immune response. LST was used in several vaccination studies but was discontinued due to the lack of a reliable supply and because it was never made under cGMP conditions [<xref rid="B130-pathogens-11-00431" ref-type="bibr">130</xref>]. The availability of a leishmanin reagent made under cGMP conditions may be a critical element in advancing <italic toggle="yes">Leishmania</italic> vaccine studies. Recent estimates indicate that 300&#8211;830 million doses for a vaccine preventing VL and 557&#8211;1400 million doses for a vaccine preventing CL over a 10-year period [<xref rid="B131-pathogens-11-00431" ref-type="bibr">131</xref>] would be needed. Such estimates are helpful in advancing the vaccine development efforts through agencies with a public health agenda in the endemic countries.</p><p>Additionally, the vaccine strategies described above for CL have not been explored against New World <italic toggle="yes">Leishmania</italic> species. For example, immunization with <italic toggle="yes">LmCen<sup>-/-</sup></italic> has not yet been tested against the New World species of <italic toggle="yes">Leishmania;</italic> thus, its potential against these <italic toggle="yes">Leishmania</italic> species remains unrealized. To address that, we recently showed that a <italic toggle="yes">centrin</italic> deletion mutant in the <italic toggle="yes">L. mexicana</italic> background produced using CRISPR/Cas9-based targeting also conferred protection in pre-clinical animal models against homologous <italic toggle="yes">L. mexicana</italic> and against heterologous <italic toggle="yes">L. donovani</italic> challenge [<xref rid="B123-pathogens-11-00431" ref-type="bibr">123</xref>] (unpublished data). Taken together, using new technologies and exploiting established mechanism of leishmaniasis, it is possible to develop vaccine candidates that are safe and efficacious for human use against many forms of leishmaniasis. </p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, H.L.N. and A.R.S.; writing&#8212;original draft preparation, G.V., S.G. and T.P.-F.; writing&#8212;review and editing, G.V., P.B., S.G., T.P.-F., T.O., R.D., H.L.N. and A.R.S.; visualization, G.V.; funding acquisition, H.L.N. and A.R.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was funded by National Institute of Health (NIH) grants R03AI144253-02 and R21AI138555-02 (ARS) and intramural funding from FDA (HLN).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The findings of this study are an informal communication and represent the authors&#8217; own best judgments. These comments do not bind or obligate the FDA.</p></notes><ref-list><title>References</title><ref id="B1-pathogens-11-00431"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frasca</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scherrer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Henao-Martinez</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramanan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>J.A.</given-names></name></person-group><article-title>A Review of Leishmaniasis: Current Knowledge and Future Directions</article-title><source>Curr. Trop. Med. Rep.</source><year>2021</year><volume>8</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s40475-021-00232-7</pub-id><pub-id pub-id-type="pmid">33747716</pub-id><pub-id pub-id-type="pmcid">PMC7966913</pub-id></element-citation></ref><ref id="B2-pathogens-11-00431"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Guerrero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Quintanilla-Cedillo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ruiz-Esmenjaud</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arenas</surname><given-names>R.</given-names></name></person-group><article-title>Leishmaniasis: A review</article-title><source>F1000Research</source><year>2017</year><volume>6</volume><fpage>750</fpage><pub-id pub-id-type="doi">10.12688/f1000research.11120.1</pub-id><pub-id pub-id-type="pmid">28649370</pub-id><pub-id pub-id-type="pmcid">PMC5464238</pub-id></element-citation></ref><ref id="B3-pathogens-11-00431"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reithinger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dujardin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Louzir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pirmez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brooker</surname><given-names>S.</given-names></name></person-group><article-title>Cutaneous leishmaniasis</article-title><source>Lancet Infect. Dis.</source><year>2007</year><volume>7</volume><fpage>581</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(07)70209-8</pub-id><pub-id pub-id-type="pmid">17714672</pub-id></element-citation></ref><ref id="B4-pathogens-11-00431"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basu</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>M.</given-names></name></person-group><article-title>Macrophage and Leishmania: An unacceptable coexistence</article-title><source>Crit. Rev. Microbiol.</source><year>2005</year><volume>31</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1080/10408410591005101</pub-id><pub-id pub-id-type="pmid">16170905</pub-id></element-citation></ref><ref id="B5-pathogens-11-00431"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Velez</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Bern</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Desjeux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jannin</surname><given-names>J.</given-names></name><name name-style="western"><surname>den Boer</surname><given-names>M.</given-names></name><collab>WHO Leishmaniasis Control Team</collab></person-group><article-title>Leishmaniasis worldwide and global estimates of its incidence</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e35671</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035671</pub-id><pub-id pub-id-type="pmid">22693548</pub-id><pub-id pub-id-type="pmcid">PMC3365071</pub-id></element-citation></ref><ref id="B6-pathogens-11-00431"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Leishmaniasis in high-burden countries: An epidemiological update based on data reported in 2014</article-title><source>Wkly. Epidemiol. Rec.</source><year>2016</year><volume>91</volume><fpage>10</fpage><pub-id pub-id-type="pmid">27263128</pub-id></element-citation></ref><ref id="B7-pathogens-11-00431"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasidharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saudagar</surname><given-names>P.</given-names></name></person-group><article-title>Leishmaniasis: Where are we and where are we heading?</article-title><source>Parasitol. Res.</source><year>2021</year><volume>120</volume><fpage>1541</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1007/s00436-021-07139-2</pub-id><pub-id pub-id-type="pmid">33825036</pub-id></element-citation></ref><ref id="B8-pathogens-11-00431"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Karmakar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lypaczewski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simonyan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Coutinho-Abreu</surname><given-names>I.V.</given-names></name><etal/></person-group><article-title>A second generation leishmanization vaccine with a markerless attenuated <italic toggle="yes">Leishmania major</italic> strain using CRISPR gene editing</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3461</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17154-z</pub-id><pub-id pub-id-type="pmid">32651371</pub-id><pub-id pub-id-type="pmcid">PMC7351751</pub-id></element-citation></ref><ref id="B9-pathogens-11-00431"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bumb</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name></person-group><article-title>Radiofrequency-induced heat therapy as first-line treatment for cutaneous leishmaniasis</article-title><source>Expert. Rev. Anti-Infect. Ther.</source><year>2011</year><volume>9</volume><fpage>623</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1586/eri.11.50</pub-id><pub-id pub-id-type="pmid">21692665</pub-id></element-citation></ref><ref id="B10-pathogens-11-00431"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Row</surname><given-names>R.</given-names></name></person-group><article-title>The Curative Value of Leishmania Culture &#8220;Vaccine&#8221; in Oriental Sore</article-title><source>Br. Med. J.</source><year>1912</year><volume>1</volume><fpage>540</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1136/bmj.1.2671.540</pub-id><pub-id pub-id-type="pmid">20766048</pub-id><pub-id pub-id-type="pmcid">PMC2344602</pub-id></element-citation></ref><ref id="B11-pathogens-11-00431"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khamesipour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dowlati</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Asilian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hashemi-Fesharki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Javadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Noazin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Modabber</surname><given-names>F.</given-names></name></person-group><article-title>Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3642</fpage><lpage>3648</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.02.015</pub-id><pub-id pub-id-type="pmid">15882524</pub-id></element-citation></ref><ref id="B12-pathogens-11-00431"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seyed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S.</given-names></name></person-group><article-title>Translating Observations from Leishmanization into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies against Leishmania</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1227</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01227</pub-id><pub-id pub-id-type="pmid">29922288</pub-id><pub-id pub-id-type="pmcid">PMC5996938</pub-id></element-citation></ref><ref id="B13-pathogens-11-00431"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedzierski</surname><given-names>L.</given-names></name></person-group><article-title>Leishmaniasis Vaccine: Where are We Today?</article-title><source>J. Glob. Infect. Dis.</source><year>2010</year><volume>2</volume><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.4103/0974-777X.62881</pub-id><pub-id pub-id-type="pmid">20606974</pub-id><pub-id pub-id-type="pmcid">PMC2889658</pub-id></element-citation></ref><ref id="B14-pathogens-11-00431"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moafi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezvan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sherkat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Taleban</surname><given-names>R.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania</italic> Vaccines Entered in Clinical Trials: A Review of Literature</article-title><source>Int. J. Prev. Med.</source><year>2019</year><volume>10</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.4103/ijpvm.IJPVM_116_18</pub-id><pub-id pub-id-type="pmid">31360342</pub-id><pub-id pub-id-type="pmcid">PMC6592111</pub-id></element-citation></ref><ref id="B15-pathogens-11-00431"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name></person-group><article-title>Vaccine Development against <italic toggle="yes">Leishmania donovani</italic></article-title><source>Front. Immunol.</source><year>2012</year><volume>3</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2012.00099</pub-id><pub-id pub-id-type="pmid">22615707</pub-id><pub-id pub-id-type="pmcid">PMC3351671</pub-id></element-citation></ref><ref id="B16-pathogens-11-00431"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armijos</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Weigel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Aviles</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Racines</surname><given-names>J.</given-names></name></person-group><article-title>Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up</article-title><source>J. Infect. Dis.</source><year>1998</year><volume>177</volume><fpage>1352</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1086/515265</pub-id><pub-id pub-id-type="pmid">9593024</pub-id></element-citation></ref><ref id="B17-pathogens-11-00431"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name></person-group><article-title>A radioattenuated <italic toggle="yes">Leishmania major</italic> vaccine markedly increases the resistance of CBA mice to subsequent infection with <italic toggle="yes">Leishmania mexicana mexicana</italic></article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1982</year><volume>76</volume><fpage>646</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(82)90232-2</pub-id><pub-id pub-id-type="pmid">7179418</pub-id></element-citation></ref><ref id="B18-pathogens-11-00431"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayrink</surname><given-names>W.</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Magalhaes</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Michalick</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>P.</given-names></name></person-group><article-title>A field trial of a vaccine against American dermal leishmaniasis</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1979</year><volume>73</volume><fpage>385</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(79)90159-7</pub-id><pub-id pub-id-type="pmid">555064</pub-id></element-citation></ref><ref id="B19-pathogens-11-00431"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzochi</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Marzochi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Grativol</surname><given-names>N.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Confort</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Modabber</surname><given-names>F.</given-names></name></person-group><article-title>Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil</article-title><source>Mem. Inst. Oswaldo Cruz.</source><year>1998</year><volume>93</volume><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1590/S0074-02761998000200014</pub-id><pub-id pub-id-type="pmid">9698895</pub-id></element-citation></ref><ref id="B20-pathogens-11-00431"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendonca</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Mayrink</surname><given-names>W.</given-names></name><name name-style="western"><surname>Restom</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Conceicao-Silva</surname><given-names>F.</given-names></name><name name-style="western"><surname>Da-Cruz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bertho</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Da Costa</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Genaro</surname><given-names>O.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>V.P.</given-names></name><etal/></person-group><article-title>Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1995</year><volume>53</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1995.53.195</pub-id><pub-id pub-id-type="pmid">7677224</pub-id></element-citation></ref><ref id="B21-pathogens-11-00431"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palatnik-de-Sousa</surname><given-names>C.B.</given-names></name></person-group><article-title>Vaccines for leishmaniasis in the fore coming 25 years</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>1709</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.023</pub-id><pub-id pub-id-type="pmid">18295939</pub-id></element-citation></ref><ref id="B22-pathogens-11-00431"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velez</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>del Pilar Agudelo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arbelaez</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>K.</given-names></name><name name-style="western"><surname>Robledo</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Puerta</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zicker</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Modabber</surname><given-names>F.</given-names></name></person-group><article-title>Safety and immunogenicity of a killed <italic toggle="yes">Leishmania (L.) amazonensis</italic> vaccine against cutaneous leishmaniasis in Colombia: A randomized controlled trial</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2000</year><volume>94</volume><fpage>698</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/S0035-9203(00)90239-6</pub-id><pub-id pub-id-type="pmid">11198661</pub-id></element-citation></ref><ref id="B23-pathogens-11-00431"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Possibilities and challenges for developing a successful vaccine for leishmaniasis</article-title><source>Parasit. Vectors</source><year>2016</year><volume>9</volume><fpage>277</fpage><pub-id pub-id-type="doi">10.1186/s13071-016-1553-y</pub-id><pub-id pub-id-type="pmid">27175732</pub-id><pub-id pub-id-type="pmcid">PMC4866332</pub-id></element-citation></ref><ref id="B24-pathogens-11-00431"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeronimo</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vedvick</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Jernigan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Petri</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Pearson</surname><given-names>R.D.</given-names></name></person-group><article-title>Identification of <italic toggle="yes">Leishmania chagasi</italic> antigens recognized by human lymphocytes</article-title><source>J. Infect. Dis.</source><year>1995</year><volume>172</volume><fpage>1055</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1093/infdis/172.4.1055</pub-id><pub-id pub-id-type="pmid">7561180</pub-id></element-citation></ref><ref id="B25-pathogens-11-00431"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravindran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name></person-group><article-title>Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis</article-title><source>Curr. Mol. Med.</source><year>2004</year><volume>4</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.2174/1566524043360212</pub-id><pub-id pub-id-type="pmid">15357218</pub-id></element-citation></ref><ref id="B26-pathogens-11-00431"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giunchetti</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Correa-Oliveira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martins-Filho</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Teixeira-Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roatt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>de Oliveira Aguiar-Soares</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>das Dores Moreira</surname><given-names>N.</given-names></name><name name-style="western"><surname>Malaquias</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Mota e Castro</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Immunogenicity of a killed <italic toggle="yes">Leishmania</italic> vaccine with saponin adjuvant in dogs</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7674</fpage><lpage>7686</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.08.009</pub-id><pub-id pub-id-type="pmid">17913311</pub-id><pub-id pub-id-type="pmcid">PMC7115514</pub-id></element-citation></ref><ref id="B27-pathogens-11-00431"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Brito</surname><given-names>R.C.F.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>J.M.O.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>L.E.S.</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Mathias</surname><given-names>F.A.S.</given-names></name><name name-style="western"><surname>Roatt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Aguiar-Soares</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Resende</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>A.B.</given-names></name></person-group><article-title>Peptide Vaccines for Leishmaniasis</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1043</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01043</pub-id><pub-id pub-id-type="pmid">29868006</pub-id><pub-id pub-id-type="pmcid">PMC5958606</pub-id></element-citation></ref><ref id="B28-pathogens-11-00431"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Castes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trujillo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Convit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.A.</given-names></name></person-group><article-title>Immunotherapy with live BCG plus heat killed <italic toggle="yes">Leishmania</italic> induces a T helper 1-like response in American cutaneous leishmaniasis patients</article-title><source>Parasite Immunol.</source><year>2000</year><volume>22</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3024.2000.00278.x</pub-id><pub-id pub-id-type="pmid">10652119</pub-id></element-citation></ref><ref id="B29-pathogens-11-00431"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Momeni</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Jalayer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Emamjomeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khamesipour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zicker</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ghassemi</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Dowlati</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sharifi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aminjavaheri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shafiei</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A randomised, double-blind, controlled trial of a killed <italic toggle="yes">L. major</italic> vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00220-5</pub-id><pub-id pub-id-type="pmid">10073725</pub-id></element-citation></ref><ref id="B30-pathogens-11-00431"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharifi</surname><given-names>I.</given-names></name><name name-style="western"><surname>FeKri</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Aflatonian</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Khamesipour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nadim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Momeni</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Dowlati</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Godal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zicker</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Randomised vaccine trial of single dose of killed <italic toggle="yes">Leishmania major</italic> plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1540</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)09552-X</pub-id><pub-id pub-id-type="pmid">10326536</pub-id></element-citation></ref><ref id="B31-pathogens-11-00431"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharples</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Castes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Convit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>J.M.</given-names></name></person-group><article-title>Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: Antibody responses to mycobacterial and leishmanial antigens</article-title><source>Vaccine</source><year>1994</year><volume>12</volume><fpage>1402</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)90149-X</pub-id><pub-id pub-id-type="pmid">7887018</pub-id></element-citation></ref><ref id="B32-pathogens-11-00431"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armijos</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Weigel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>J.</given-names></name></person-group><article-title>Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: How long does protection last?</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>187</volume><fpage>1959</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1086/375399</pub-id><pub-id pub-id-type="pmid">12792873</pub-id></element-citation></ref><ref id="B33-pathogens-11-00431"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armijos</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Weigel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Calvopina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cevallos</surname><given-names>W.</given-names></name><name name-style="western"><surname>Correa</surname><given-names>J.</given-names></name></person-group><article-title>Safety, immunogenecity, and efficacy of an autoclaved <italic toggle="yes">Leishmania amazonensis</italic> vaccine plus BCG adjuvant against New World cutaneous leishmaniasis</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>1320</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.06.002</pub-id><pub-id pub-id-type="pmid">15003662</pub-id></element-citation></ref><ref id="B34-pathogens-11-00431"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohebali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khamesipour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mobedi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zarei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hashemi-Fesharki</surname><given-names>R.</given-names></name></person-group><article-title>Double-blind randomized efficacy field trial of alum precipitated autoclaved <italic toggle="yes">Leishmania major</italic> vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>4097</fpage><lpage>4100</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.058</pub-id><pub-id pub-id-type="pmid">15364462</pub-id></element-citation></ref><ref id="B35-pathogens-11-00431"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.B.</given-names></name></person-group><article-title>A review of vaccine development and research for industry animals in Korea</article-title><source>Clin. Exp. Vaccine Res.</source><year>2012</year><volume>1</volume><fpage>18</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.7774/cevr.2012.1.1.18</pub-id><pub-id pub-id-type="pmid">23596575</pub-id><pub-id pub-id-type="pmcid">PMC3623508</pub-id></element-citation></ref><ref id="B36-pathogens-11-00431"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagill</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine candidates for leishmaniasis: A review</article-title><source>Int. Immunopharmacol.</source><year>2011</year><volume>11</volume><fpage>1464</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2011.05.008</pub-id><pub-id pub-id-type="pmid">21616175</pub-id></element-citation></ref><ref id="B37-pathogens-11-00431"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Oliveira</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Alves Pereira</surname><given-names>V.R.</given-names></name></person-group><article-title>Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis</article-title><source>Hum. Vaccines Immunother.</source><year>2020</year><volume>16</volume><fpage>919</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1678998</pub-id><pub-id pub-id-type="pmcid">PMC7227727</pub-id><pub-id pub-id-type="pmid">31634036</pub-id></element-citation></ref><ref id="B38-pathogens-11-00431"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Croft</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khamesipour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Case study for a vaccine against leishmaniasis</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><issue>(Suppl. 2)</issue><fpage>B244</fpage><lpage>B249</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.080</pub-id><pub-id pub-id-type="pmid">23598489</pub-id></element-citation></ref><ref id="B39-pathogens-11-00431"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name></person-group><article-title>Leishmaniasis: Vaccine candidates and perspectives</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>3834</fpage><lpage>3842</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.03.068</pub-id><pub-id pub-id-type="pmid">22475861</pub-id></element-citation></ref><ref id="B40-pathogens-11-00431"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Piazza</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>The development and clinical evaluation of second-generation leishmaniasis vaccines</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.005</pub-id><pub-id pub-id-type="pmid">22085553</pub-id><pub-id pub-id-type="pmcid">PMC3359766</pub-id></element-citation></ref><ref id="B41-pathogens-11-00431"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hofmeyer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jayashankar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vergara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rolf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Misquith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laurance</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>V.S.</given-names></name><etal/></person-group><article-title>From mouse to man: Safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE</article-title><source>Clin. Transl. Immunol.</source><year>2015</year><volume>4</volume><fpage>e35</fpage><pub-id pub-id-type="doi">10.1038/cti.2015.6</pub-id><pub-id pub-id-type="pmid">26175894</pub-id><pub-id pub-id-type="pmcid">PMC4488838</pub-id></element-citation></ref><ref id="B42-pathogens-11-00431"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezvan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moafi</surname><given-names>M.</given-names></name></person-group><article-title>An overview on <italic toggle="yes">Leishmania</italic> vaccines: A narrative review article</article-title><source>Vet. Res. Forum.</source><year>2015</year><volume>6</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25992245</pub-id><pub-id pub-id-type="pmcid">PMC4405679</pub-id></element-citation></ref><ref id="B43-pathogens-11-00431"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillespie</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Beaumier</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hayward</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M.E.</given-names></name></person-group><article-title>Status of vaccine research and development of vaccines for leishmaniasis</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2992</fpage><lpage>2995</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.12.071</pub-id><pub-id pub-id-type="pmid">26973063</pub-id></element-citation></ref><ref id="B44-pathogens-11-00431"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>3531</fpage><lpage>3537</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.02.096</pub-id><pub-id pub-id-type="pmid">21414377</pub-id></element-citation></ref><ref id="B45-pathogens-11-00431"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llanos-Cuentas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ashman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Bogatzki</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7427</fpage><lpage>7435</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.092</pub-id><pub-id pub-id-type="pmid">20851080</pub-id></element-citation></ref><ref id="B46-pathogens-11-00431"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpedo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huston</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Holcomb</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pacheco-Fernandez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name></person-group><article-title>From infection to vaccination: Reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection</article-title><source>Expert Rev. Vaccines</source><year>2021</year><volume>20</volume><fpage>1431</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1080/14760584.2021.1969231</pub-id><pub-id pub-id-type="pmid">34511000</pub-id></element-citation></ref><ref id="B47-pathogens-11-00431"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Kimblin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Secundino</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kamhawi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawyer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name></person-group><article-title>Vector transmission of leishmania abrogates vaccine-induced protective immunity</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000484</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000484</pub-id><pub-id pub-id-type="pmid">19543375</pub-id><pub-id pub-id-type="pmcid">PMC2691580</pub-id></element-citation></ref><ref id="B48-pathogens-11-00431"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawyer</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Charmoy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ribeiro-Gomes</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Stamper</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name></person-group><article-title>Evaluation of recombinant <italic toggle="yes">Leishmania</italic> polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted <italic toggle="yes">Leishmania major</italic> in C57BL/6 mice</article-title><source>J. Immunol.</source><year>2012</year><volume>189</volume><fpage>4832</fpage><lpage>4841</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201676</pub-id><pub-id pub-id-type="pmid">23045616</pub-id><pub-id pub-id-type="pmcid">PMC3596879</pub-id></element-citation></ref><ref id="B49-pathogens-11-00431"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lawyer</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Elnaiem</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Meneses</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><etal/></person-group><article-title>KSAC, a defined <italic toggle="yes">Leishmania</italic> antigen, plus adjuvant protects against the virulence of <italic toggle="yes">L. major</italic> transmitted by its natural vector <italic toggle="yes">Phlebotomus duboscqi</italic></article-title><source>PLoS Negl. Trop. Dis.</source><year>2012</year><volume>6</volume><elocation-id>e1610</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001610</pub-id><pub-id pub-id-type="pmid">22509423</pub-id><pub-id pub-id-type="pmcid">PMC3317914</pub-id></element-citation></ref><ref id="B50-pathogens-11-00431"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sizova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nikolaev</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>P.A.</given-names></name></person-group><article-title>Synthetic glycovaccine protects against the bite of leishmania-infected sand flies</article-title><source>J. Infect. Dis.</source><year>2006</year><volume>194</volume><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1086/505584</pub-id><pub-id pub-id-type="pmid">16845636</pub-id><pub-id pub-id-type="pmcid">PMC2839923</pub-id></element-citation></ref><ref id="B51-pathogens-11-00431"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tavares</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Pitombo</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Fukutani</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Barral</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Barral-Netto</surname><given-names>M.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Lutzomyia longipalpis</italic> saliva or salivary protein LJM19 protects against <italic toggle="yes">Leishmania braziliensis</italic> and the saliva of its vector, <italic toggle="yes">Lutzomyia intermedia</italic></article-title><source>PLoS Negl. Trop. Dis.</source><year>2011</year><volume>5</volume><elocation-id>e1169</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001169</pub-id><pub-id pub-id-type="pmid">21655303</pub-id><pub-id pub-id-type="pmcid">PMC3104964</pub-id></element-citation></ref><ref id="B52-pathogens-11-00431"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meneses</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Elnaiem</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Kamhawi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>J.G.</given-names></name></person-group><article-title>Immunity to sand fly salivary protein LJM11 modulates host response to vector-transmitted leishmania conferring ulcer-free protection</article-title><source>J. Investig. Dermatol.</source><year>2012</year><volume>132</volume><fpage>2735</fpage><lpage>2743</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.205</pub-id><pub-id pub-id-type="pmid">22739793</pub-id><pub-id pub-id-type="pmcid">PMC3461249</pub-id></element-citation></ref><ref id="B53-pathogens-11-00431"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Laughinghouse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Elnaiem</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Kamhawi</surname><given-names>S.</given-names></name></person-group><article-title>Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for <italic toggle="yes">Leishmania</italic></article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000441</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000441</pub-id><pub-id pub-id-type="pmid">19461875</pub-id><pub-id pub-id-type="pmcid">PMC2677456</pub-id></element-citation></ref><ref id="B54-pathogens-11-00431"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giorgobiani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guimaraes-Costa</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Abdeladhim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oristian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tskhvaradze</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tsertsvadze</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zakalashvili</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Kamhawi</surname><given-names>S.</given-names></name></person-group><article-title>Immunity to vector saliva is compromised by short sand fly seasons in endemic regions with temperate climates</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>7990</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-64820-9</pub-id><pub-id pub-id-type="pmid">32409684</pub-id><pub-id pub-id-type="pmcid">PMC7224377</pub-id></element-citation></ref><ref id="B55-pathogens-11-00431"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Bahloul</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robbana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Askri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dellagi</surname><given-names>K.</given-names></name></person-group><article-title>A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to <italic toggle="yes">L. major</italic></article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>1631</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.10.046</pub-id><pub-id pub-id-type="pmid">15068845</pub-id></element-citation></ref><ref id="B56-pathogens-11-00431"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurunathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Charest</surname><given-names>H.</given-names></name><name name-style="western"><surname>Glaichenhaus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with <italic toggle="yes">Leishmania major</italic></article-title><source>J. Exp. Med.</source><year>1997</year><volume>186</volume><fpage>1137</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1084/jem.186.7.1137</pub-id><pub-id pub-id-type="pmid">9314562</pub-id><pub-id pub-id-type="pmcid">PMC2199076</pub-id></element-citation></ref><ref id="B57-pathogens-11-00431"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>F.Y.</given-names></name></person-group><article-title>Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of <italic toggle="yes">L. major</italic></article-title><source>Immunology</source><year>1995</year><volume>84</volume><fpage>173</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">7750991</pub-id><pub-id pub-id-type="pmcid">PMC1415107</pub-id></element-citation></ref><ref id="B58-pathogens-11-00431"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Scharton-Kersten</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rowton</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Hengge</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bouloc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Udey</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>J.C.</given-names></name></person-group><article-title>Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis</article-title><source>Hum. Gene Ther.</source><year>1998</year><volume>9</volume><fpage>1899</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1089/hum.1998.9.13-1899</pub-id><pub-id pub-id-type="pmid">9741428</pub-id></element-citation></ref><ref id="B59-pathogens-11-00431"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Fuertes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perez-Jimenez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vila-Coro</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Konig</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Junghans</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wittig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Timon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against <italic toggle="yes">Leishmania major</italic> infection in mice</article-title><source>Vaccine</source><year>2002</year><volume>21</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00450-4</pub-id><pub-id pub-id-type="pmid">12450700</pub-id></element-citation></ref><ref id="B60-pathogens-11-00431"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marques-da-Silva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Vilela</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Masioli</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Afonso</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Rezende</surname><given-names>S.A.</given-names></name></person-group><article-title>Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against <italic toggle="yes">Leishmania chagasi</italic> intravenous challenge</article-title><source>Parasitol. Res.</source><year>2005</year><volume>98</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s00436-005-0008-8</pub-id><pub-id pub-id-type="pmid">16261353</pub-id></element-citation></ref><ref id="B61-pathogens-11-00431"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melby</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania donovani</italic> p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>4719</fpage><lpage>4725</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.8.4719-4725.2001</pub-id><pub-id pub-id-type="pmid">11447143</pub-id><pub-id pub-id-type="pmcid">PMC98557</pub-id></element-citation></ref><ref id="B62-pathogens-11-00431"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samant</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccine against visceral leishmaniasis: A promising approach for prevention and control</article-title><source>Parasite Immunol.</source><year>2016</year><volume>38</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/pim.12315</pub-id><pub-id pub-id-type="pmid">27009772</pub-id></element-citation></ref><ref id="B63-pathogens-11-00431"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalo</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>del Real</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heljasvaara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larraga</surname><given-names>V.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M.</given-names></name></person-group><article-title>A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the <italic toggle="yes">Leishmania infantum</italic> P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>1226</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00427-3</pub-id><pub-id pub-id-type="pmid">11803085</pub-id></element-citation></ref><ref id="B64-pathogens-11-00431"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kardani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>S.</given-names></name></person-group><article-title>Prime-boost vaccine strategy against viral infections: Mechanisms and benefits</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.062</pub-id><pub-id pub-id-type="pmid">26691569</pub-id></element-citation></ref><ref id="B65-pathogens-11-00431"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramiro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zarate</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucientes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Larraga</surname><given-names>V.</given-names></name></person-group><article-title>Protection in dogs against visceral leishmaniasis caused by <italic toggle="yes">Leishmania infantum</italic> is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>2474</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00032-X</pub-id><pub-id pub-id-type="pmid">12744881</pub-id></element-citation></ref><ref id="B66-pathogens-11-00431"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marcen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Peris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Colmenares</surname><given-names>M.</given-names></name><name name-style="western"><surname>Larraga</surname><given-names>V.</given-names></name></person-group><article-title>Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.021</pub-id><pub-id pub-id-type="pmid">18093705</pub-id></element-citation></ref><ref id="B67-pathogens-11-00431"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mistry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keding</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gabe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>E.</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Marco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colloca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siani</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005527</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005527</pub-id><pub-id pub-id-type="pmid">28498840</pub-id><pub-id pub-id-type="pmcid">PMC5443534</pub-id></element-citation></ref><ref id="B68-pathogens-11-00431"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younis</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>E.A.G.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Furini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Keding</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carraro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Musa</surname><given-names>A.E.A.</given-names></name><name name-style="western"><surname>Abdarahaman</surname><given-names>M.A.A.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan</article-title><source>Mol. Ther.</source><year>2021</year><volume>29</volume><fpage>2366</fpage><lpage>2377</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.03.020</pub-id><pub-id pub-id-type="pmid">33781913</pub-id><pub-id pub-id-type="pmcid">PMC8261165</pub-id></element-citation></ref><ref id="B69-pathogens-11-00431"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA Vaccines-How Far From Clinical Use?</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3605</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id><pub-id pub-id-type="pmid">30445702</pub-id></element-citation></ref><ref id="B70-pathogens-11-00431"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Avishek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis&#8212;Discovery and implications</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>241</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00241</pub-id><pub-id pub-id-type="pmid">24904589</pub-id><pub-id pub-id-type="pmcid">PMC4033241</pub-id></element-citation></ref><ref id="B71-pathogens-11-00431"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silvestre</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cordeiro-da-Silva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ouaissi</surname><given-names>A.</given-names></name></person-group><article-title>Live attenuated <italic toggle="yes">Leishmania</italic> vaccines: A potential strategic alternative</article-title><source>Arch. Immunol. Ther. Exp.</source><year>2008</year><volume>56</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s00005-008-0010-9</pub-id><pub-id pub-id-type="pmid">18373245</pub-id></element-citation></ref><ref id="B72-pathogens-11-00431"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peacock</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Seeger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Quail</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adlem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tivey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aslett</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Comparative genomic analysis of three <italic toggle="yes">Leishmania</italic> species that cause diverse human disease</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>839</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1038/ng2053</pub-id><pub-id pub-id-type="pmid">17572675</pub-id><pub-id pub-id-type="pmcid">PMC2592530</pub-id></element-citation></ref><ref id="B73-pathogens-11-00431"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daneshvar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R.S.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania mexicana</italic> and <italic toggle="yes">Leishmania major</italic>: Attenuation of wild-type parasites and vaccination with the attenuated lines</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>187</volume><fpage>1662</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1086/374783</pub-id><pub-id pub-id-type="pmid">12721947</pub-id></element-citation></ref><ref id="B74-pathogens-11-00431"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Handman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spithill</surname><given-names>T.W.</given-names></name></person-group><article-title>Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of <italic toggle="yes">Leishmania major</italic> and importance of route of injection</article-title><source>Aust. J. Exp. Biol. Med. Sci.</source><year>1984</year><volume>62</volume><issue-part>Pt 2</issue-part><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/icb.1984.14</pub-id><pub-id pub-id-type="pmid">6466205</pub-id></element-citation></ref><ref id="B75-pathogens-11-00431"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorczynski</surname><given-names>R.M.</given-names></name></person-group><article-title>Immunization of susceptible BALB/c mice against <italic toggle="yes">Leishmania braziliensis</italic>. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes</article-title><source>Cell. Immunol.</source><year>1985</year><volume>94</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/0008-8749(85)90081-4</pub-id><pub-id pub-id-type="pmid">4016960</pub-id></element-citation></ref><ref id="B76-pathogens-11-00431"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bovay</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mauel</surname><given-names>J.</given-names></name></person-group><article-title>Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent <italic toggle="yes">Leishmania major</italic> challenge</article-title><source>Parasite Immunol.</source><year>1993</year><volume>15</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.1993.tb00587.x</pub-id><pub-id pub-id-type="pmid">8446467</pub-id></element-citation></ref><ref id="B77-pathogens-11-00431"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimsey</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Theodos</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mitchen</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Turco</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Titus</surname><given-names>R.G.</given-names></name></person-group><article-title>An avirulent lipophosphoglycan-deficient <italic toggle="yes">Leishmania major</italic> clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent <italic toggle="yes">L. major</italic></article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>5205</fpage><lpage>5213</lpage><pub-id pub-id-type="doi">10.1128/iai.61.12.5205-5213.1993</pub-id><pub-id pub-id-type="pmid">7901166</pub-id><pub-id pub-id-type="pmcid">PMC281302</pub-id></element-citation></ref><ref id="B78-pathogens-11-00431"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Breton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kundig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fillion</surname><given-names>I.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ouellette</surname><given-names>M.</given-names></name></person-group><article-title>Reduced infectivity of a <italic toggle="yes">Leishmania donovani</italic> biopterin transporter genetic mutant and its use as an attenuated strain for vaccination</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.1.62-68.2002</pub-id><pub-id pub-id-type="pmid">11748164</pub-id><pub-id pub-id-type="pmcid">PMC127620</pub-id></element-citation></ref><ref id="B79-pathogens-11-00431"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Matlashewski</surname><given-names>G.</given-names></name></person-group><article-title>Characterization of the A2-A2rel gene cluster in <italic toggle="yes">Leishmania donovani</italic>: Involvement of A2 in visceralization during infection</article-title><source>Mol. Microbiol.</source><year>2001</year><volume>39</volume><fpage>935</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2001.02286.x</pub-id><pub-id pub-id-type="pmid">11251814</pub-id></element-citation></ref><ref id="B80-pathogens-11-00431"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silvestre</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cordeiro-Da-Silva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santarem</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vergnes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sereno</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ouaissi</surname><given-names>A.</given-names></name></person-group><article-title>SIR2-deficient <italic toggle="yes">Leishmania infantum</italic> induces a defined IFN-gamma/IL-10 pattern that correlates with protection</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>3161</fpage><lpage>3170</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.5.3161</pub-id><pub-id pub-id-type="pmid">17709531</pub-id></element-citation></ref><ref id="B81-pathogens-11-00431"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrion</surname><given-names>J.</given-names></name><name name-style="western"><surname>Folgueira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fresno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Requena</surname><given-names>J.M.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania infantum HSP70-II</italic> null mutant as candidate vaccine against leishmaniasis: A preliminary evaluation</article-title><source>Parasit. Vectors</source><year>2011</year><volume>4</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-4-150</pub-id><pub-id pub-id-type="pmid">21794145</pub-id><pub-id pub-id-type="pmcid">PMC3199857</pub-id></element-citation></ref><ref id="B82-pathogens-11-00431"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santi</surname><given-names>A.M.M.</given-names></name><name name-style="western"><surname>Lanza</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Tunes</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Fiuza</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Orfano</surname><given-names>A.D.S.</given-names></name><name name-style="western"><surname>de Carvalho</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Frezard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>A.L.B.</given-names></name><name name-style="western"><surname>Murta</surname><given-names>S.M.F.</given-names></name><etal/></person-group><article-title>Growth arrested live-attenuated <italic toggle="yes">Leishmania infantum</italic> KHARON1 null mutants display cytokinesis defect and protective immunity in mice</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>11627</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-30076-7</pub-id><pub-id pub-id-type="pmid">30072701</pub-id><pub-id pub-id-type="pmcid">PMC6072785</pub-id></element-citation></ref><ref id="B83-pathogens-11-00431"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Terrazas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Characterization of cross-protection by genetically modified live-attenuated <italic toggle="yes">Leishmania donovani</italic> parasites against <italic toggle="yes">Leishmania mexicana</italic></article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>3513</fpage><lpage>3527</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303145</pub-id><pub-id pub-id-type="pmid">25156362</pub-id><pub-id pub-id-type="pmcid">PMC6480318</pub-id></element-citation></ref><ref id="B84-pathogens-11-00431"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Live attenuated <italic toggle="yes">Leishmania donovani</italic> p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>2138</fpage><lpage>2149</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202801</pub-id><pub-id pub-id-type="pmid">23338240</pub-id><pub-id pub-id-type="pmcid">PMC3578143</pub-id></element-citation></ref><ref id="B85-pathogens-11-00431"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samant</surname><given-names>M.</given-names></name></person-group><article-title>Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis</article-title><source>Parasite Immunol.</source><year>2020</year><volume>42</volume><fpage>e12732</fpage><pub-id pub-id-type="doi">10.1111/pim.12732</pub-id><pub-id pub-id-type="pmid">32418227</pub-id></element-citation></ref><ref id="B86-pathogens-11-00431"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabala-Penafiel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Daneshvar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burchmore</surname><given-names>R.</given-names></name></person-group><article-title>The potential of live attenuated vaccines against Cutaneous Leishmaniasis</article-title><source>Exp. Parasitol.</source><year>2020</year><volume>210</volume><fpage>107849</fpage><pub-id pub-id-type="doi">10.1016/j.exppara.2020.107849</pub-id><pub-id pub-id-type="pmid">32027892</pub-id></element-citation></ref><ref id="B87-pathogens-11-00431"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Titus</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Gueiros-Filho</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>de Freitas</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Beverley</surname><given-names>S.M.</given-names></name></person-group><article-title>Development of a safe live Leishmania vaccine line by gene replacement</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>10267</fpage><lpage>10271</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.22.10267</pub-id><pub-id pub-id-type="pmid">7479765</pub-id><pub-id pub-id-type="pmcid">PMC40777</pub-id></element-citation></ref><ref id="B88-pathogens-11-00431"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amaral</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Teva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oliveira-Neto</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Cupolillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Porrozzi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coutinho</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Pirmez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beverley</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Study of the safety, immunogenicity and efficacy of attenuated and killed <italic toggle="yes">Leishmania</italic> (<italic toggle="yes">Leishmania</italic>) major vaccines in a rhesus monkey (<italic toggle="yes">Macaca mulatta</italic>) model of the human disease</article-title><source>Mem. Inst. Oswaldo Cruz.</source><year>2002</year><volume>97</volume><fpage>1041</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762002000700019</pub-id><pub-id pub-id-type="pmid">12471434</pub-id></element-citation></ref><ref id="B89-pathogens-11-00431"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saravia</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Escorcia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Valderrama</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arteaga</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mottram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Travi</surname><given-names>B.L.</given-names></name></person-group><article-title>Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of <italic toggle="yes">Leishmania mexicana</italic> in non-murine models</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>4247</fpage><lpage>4259</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.05.045</pub-id><pub-id pub-id-type="pmid">16216395</pub-id></element-citation></ref><ref id="B90-pathogens-11-00431"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Mottram</surname><given-names>J.C.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania mexicana</italic> cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response</article-title><source>J. Immunol.</source><year>1998</year><volume>161</volume><fpage>6794</fpage><lpage>6801</lpage><pub-id pub-id-type="pmid">9862710</pub-id></element-citation></ref><ref id="B91-pathogens-11-00431"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzonna</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Spath</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Beverley</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>Vaccination with phosphoglycan-deficient <italic toggle="yes">Leishmania major</italic> protects highly susceptible mice from virulent challenge without inducing a strong Th1 response</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>3793</fpage><lpage>3797</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.6.3793</pub-id><pub-id pub-id-type="pmid">15004184</pub-id></element-citation></ref><ref id="B92-pathogens-11-00431"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bovay</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Didisheim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mauel</surname><given-names>J.</given-names></name></person-group><article-title>Vaccination against <italic toggle="yes">Leishmania major</italic> in a CBA mouse model of infection: Role of adjuvants and mechanism of protection</article-title><source>Parasite Immunol.</source><year>1999</year><volume>21</volume><fpage>461</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3024.1999.00244.x</pub-id><pub-id pub-id-type="pmid">10476055</pub-id></element-citation></ref><ref id="B93-pathogens-11-00431"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handman</surname><given-names>E.</given-names></name></person-group><article-title>Leishmaniasis: Current status of vaccine development</article-title><source>Clin. Microbiol. Rev.</source><year>2001</year><volume>14</volume><fpage>229</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1128/CMR.14.2.229-243.2001</pub-id><pub-id pub-id-type="pmid">11292637</pub-id><pub-id pub-id-type="pmcid">PMC88972</pub-id></element-citation></ref><ref id="B94-pathogens-11-00431"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Janse</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mikolajczak</surname><given-names>S.A.</given-names></name></person-group><article-title>Genetic engineering of attenuated malaria parasites for vaccination</article-title><source>Curr. Opin. Biotechnol.</source><year>2012</year><volume>23</volume><fpage>908</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2012.04.003</pub-id><pub-id pub-id-type="pmid">22560204</pub-id></element-citation></ref><ref id="B95-pathogens-11-00431"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keitany</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smithers</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sather</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Vignali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Immunization of mice with live-attenuated late liver stage-arresting Plasmodium yoelii parasites generates protective antibody responses to preerythrocytic stages of malaria</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>5143</fpage><lpage>5153</lpage><pub-id pub-id-type="doi">10.1128/IAI.02320-14</pub-id><pub-id pub-id-type="pmid">25267837</pub-id><pub-id pub-id-type="pmcid">PMC4249261</pub-id></element-citation></ref><ref id="B96-pathogens-11-00431"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikolajczak</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Lakshmanan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fishbaugher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harupa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaushansky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Douglass</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Healer</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A next-generation genetically attenuated <italic toggle="yes">Plasmodium falciparum</italic> parasite created by triple gene deletion</article-title><source>Mol. Ther.</source><year>2014</year><volume>22</volume><fpage>1707</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1038/mt.2014.85</pub-id><pub-id pub-id-type="pmid">24827907</pub-id><pub-id pub-id-type="pmcid">PMC4435496</pub-id></element-citation></ref><ref id="B97-pathogens-11-00431"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Dankwa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Minkah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cardamone</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.I.</given-names></name></person-group><article-title>A <italic toggle="yes">Plasmodium</italic> Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice</article-title><source>Infect. Immun.</source><year>2018</year><volume>86</volume><elocation-id>e00088-18</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.00088-18</pub-id><pub-id pub-id-type="pmid">29440367</pub-id><pub-id pub-id-type="pmcid">PMC5913857</pub-id></element-citation></ref><ref id="B98-pathogens-11-00431"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Debrabant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sreenivas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Negi</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Expression of a mutant form of <italic toggle="yes">Leishmania donovani</italic> centrin reduces the growth of the parasite</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>43253</fpage><lpage>43261</lpage><pub-id pub-id-type="doi">10.1074/jbc.M106806200</pub-id><pub-id pub-id-type="pmid">11544261</pub-id></element-citation></ref><ref id="B99-pathogens-11-00431"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Debrabant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sreenivas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salisbury</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>25703</fpage><lpage>25710</lpage><pub-id pub-id-type="doi">10.1074/jbc.M402794200</pub-id><pub-id pub-id-type="pmid">15084606</pub-id></element-citation></ref><ref id="B100-pathogens-11-00431"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solanki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Generation of growth arrested <italic toggle="yes">Leishmania amastigotes</italic>: A tool to develop live attenuated vaccine candidates against visceral leishmaniasis</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3895</fpage><lpage>3901</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.05.009</pub-id><pub-id pub-id-type="pmid">24837513</pub-id></element-citation></ref><ref id="B101-pathogens-11-00431"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nylen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Intracellular replication-deficient <italic toggle="yes">Leishmania donovani</italic> induces long lasting protective immunity against visceral leishmaniasis</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>1813</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900276</pub-id><pub-id pub-id-type="pmid">19592661</pub-id></element-citation></ref><ref id="B102-pathogens-11-00431"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Karmakar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Akue</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>KuKuruga</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Live Attenuated <italic toggle="yes">Leishmania donovani</italic> Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model</article-title><source>J. Immunol.</source><year>2018</year><volume>200</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700674</pub-id><pub-id pub-id-type="pmid">29187586</pub-id><pub-id pub-id-type="pmcid">PMC6532400</pub-id></element-citation></ref><ref id="B103-pathogens-11-00431"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gedda</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Centrin-Deleted <italic toggle="yes">Leishmania donovani</italic> Parasites Help CD4<sup>+</sup> T Cells to Acquire Th1 Phenotype and Multi-Functionality Through Downregulation of CD200-CD200R Immune Inhibitory Axis</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1176</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01176</pub-id><pub-id pub-id-type="pmid">29915577</pub-id><pub-id pub-id-type="pmcid">PMC5994488</pub-id></element-citation></ref><ref id="B104-pathogens-11-00431"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Debrabant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akue</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>KuKuruga</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Live Attenuated <italic toggle="yes">Leishmania donovani</italic> Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004963</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004963</pub-id><pub-id pub-id-type="pmid">27580076</pub-id><pub-id pub-id-type="pmcid">PMC5007048</pub-id></element-citation></ref><ref id="B105-pathogens-11-00431"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Uzonna</surname><given-names>J.E.</given-names></name></person-group><article-title>The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2012</year><volume>2</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2012.00083</pub-id><pub-id pub-id-type="pmid">22919674</pub-id><pub-id pub-id-type="pmcid">PMC3417671</pub-id></element-citation></ref><ref id="B106-pathogens-11-00431"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomiotto-Pellissier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bortoleti</surname><given-names>B.T.D.S.</given-names></name><name name-style="western"><surname>Assolini</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Carloto</surname><given-names>A.C.M.</given-names></name><name name-style="western"><surname>Miranda-Sapla</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Conchon-Costa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bordignon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pavanelli</surname><given-names>W.R.</given-names></name></person-group><article-title>Macrophage Polarization in Leishmaniasis: Broadening Horizons</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2529</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02529</pub-id><pub-id pub-id-type="pmid">30429856</pub-id><pub-id pub-id-type="pmcid">PMC6220043</pub-id></element-citation></ref><ref id="B107-pathogens-11-00431"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name></person-group><article-title>Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism</article-title><source>Cytokine X</source><year>2020</year><volume>2</volume><fpage>100041</fpage><pub-id pub-id-type="doi">10.1016/j.cytox.2020.100041</pub-id><pub-id pub-id-type="pmid">33604563</pub-id><pub-id pub-id-type="pmcid">PMC7885870</pub-id></element-citation></ref><ref id="B108-pathogens-11-00431"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Kruhlak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Debrabant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Akue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kukuruga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Genetically Modified Live Attenuated <italic toggle="yes">Leishmania donovani</italic> Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>3800</fpage><lpage>3815</lpage><pub-id pub-id-type="doi">10.1128/IAI.00184-15</pub-id><pub-id pub-id-type="pmid">26169275</pub-id><pub-id pub-id-type="pmcid">PMC4567628</pub-id></element-citation></ref><ref id="B109-pathogens-11-00431"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karmakar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Paoli</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Essential Role of Neutrophils in the Protective Immune Response Induced by a Live Attenuated</article-title><source>J. Immunol.</source><year>2020</year><volume>205</volume><fpage>3333</fpage><lpage>3347</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000829</pub-id><pub-id pub-id-type="pmid">33177159</pub-id><pub-id pub-id-type="pmcid">PMC7725841</pub-id></element-citation></ref><ref id="B110-pathogens-11-00431"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro-Gomes</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>The influence of early neutrophil-Leishmania interactions on the host immune response to infection</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2012</year><volume>2</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2012.00059</pub-id><pub-id pub-id-type="pmid">22919650</pub-id><pub-id pub-id-type="pmcid">PMC3417510</pub-id></element-citation></ref><ref id="B111-pathogens-11-00431"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>O.P.</given-names></name><name name-style="western"><surname>Hasker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name><name name-style="western"><surname>Boelaert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name></person-group><article-title>Asymptomatic <italic toggle="yes">Leishmania</italic> infection: A new challenge for <italic toggle="yes">Leishmania</italic> control</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>58</volume><fpage>1424</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu102</pub-id><pub-id pub-id-type="pmid">24585564</pub-id><pub-id pub-id-type="pmcid">PMC4001287</pub-id></element-citation></ref><ref id="B112-pathogens-11-00431"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Immunization with Live Attenuated <italic toggle="yes">Leishmania donovani</italic> Centrin<sup>-/-</sup> Parasites Is Efficacious in Asymptomatic Infection</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1788</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01788</pub-id><pub-id pub-id-type="pmid">29312315</pub-id><pub-id pub-id-type="pmcid">PMC5732910</pub-id></element-citation></ref><ref id="B113-pathogens-11-00431"><label>113.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Post-Kala-Azar dermal leishmaniasis: A manual for case management and control</article-title><source>Proceedings of the Report of a WHO Consultative Meeting</source><conf-loc>Kolkata, India</conf-loc><conf-date>2&#8211;3 July 2012</conf-date><comment>WHO/HTM/NTD/IDM/2013.1</comment><fpage>29</fpage></element-citation></ref><ref id="B114-pathogens-11-00431"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gedda</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Madhukar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>O.P.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name></person-group><article-title>Post kala-azar dermal leishmaniasis: A threat to elimination program</article-title><source>PLoS Negl. Trop. Dis.</source><year>2020</year><volume>14</volume><elocation-id>e0008221</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0008221</pub-id><pub-id pub-id-type="pmid">32614818</pub-id><pub-id pub-id-type="pmcid">PMC7332242</pub-id></element-citation></ref><ref id="B115-pathogens-11-00431"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avishek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Negi</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>U.S.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name></person-group><article-title>Gene deleted live attenuated <italic toggle="yes">Leishmania</italic> vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>33059</fpage><pub-id pub-id-type="doi">10.1038/srep33059</pub-id><pub-id pub-id-type="pmid">27624408</pub-id><pub-id pub-id-type="pmcid">PMC5021981</pub-id></element-citation></ref><ref id="B116-pathogens-11-00431"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiuza</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>H.A.C.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Bartholomeu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Correa-Oliveira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>R.T.</given-names></name></person-group><article-title>Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>1785</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.01.048</pub-id><pub-id pub-id-type="pmid">23398933</pub-id></element-citation></ref><ref id="B117-pathogens-11-00431"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiuza</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>H.A.C.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Passos</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>de Mendon&#231;a</surname><given-names>L.Z.</given-names></name><name name-style="western"><surname>Lemos-Giunchetti</surname><given-names>D.A.S.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Bartholomeu</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Vaccination using live attenuated <italic toggle="yes">Leishmania donovani</italic> centrin deleted parasites induces protection in dogs against <italic toggle="yes">Leishmania infantum</italic></article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.11.039</pub-id><pub-id pub-id-type="pmid">25475955</pub-id></element-citation></ref><ref id="B118-pathogens-11-00431"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viana</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Fiuza</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bartholomeu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>da Silveira-Lemos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Dutra</surname><given-names>W.O.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>R.T.</given-names></name><etal/></person-group><article-title>Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated <italic toggle="yes">Leishmania donovani</italic> centrin deleted parasites (LdCen<sup>-/-</sup>)</article-title><source>Parasit. Vectors</source><year>2016</year><volume>9</volume><fpage>250</fpage><pub-id pub-id-type="doi">10.1186/s13071-016-1528-z</pub-id><pub-id pub-id-type="pmid">27136900</pub-id><pub-id pub-id-type="pmcid">PMC4852444</pub-id></element-citation></ref><ref id="B119-pathogens-11-00431"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGwire</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name></person-group><article-title>Leishmaniasis: Clinical syndromes and treatment</article-title><source>QJM</source><year>2014</year><volume>107</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hct116</pub-id><pub-id pub-id-type="pmid">23744570</pub-id><pub-id pub-id-type="pmcid">PMC3869292</pub-id></element-citation></ref><ref id="B120-pathogens-11-00431"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dayama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name></person-group><article-title>Diagnosis of visceral leishmaniasis</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2011</year><volume>105</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2010.09.006</pub-id><pub-id pub-id-type="pmid">21074233</pub-id><pub-id pub-id-type="pmcid">PMC2999003</pub-id></element-citation></ref><ref id="B121-pathogens-11-00431"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpedo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pacheco-Fernandez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holcomb</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Cipriano</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>B.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name></person-group><article-title>Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL)</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><fpage>685296</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.685296</pub-id><pub-id pub-id-type="pmid">34169006</pub-id><pub-id pub-id-type="pmcid">PMC8217655</pub-id></element-citation></ref><ref id="B122-pathogens-11-00431"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karmakar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Oristian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Kaviraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis</article-title><source>Commun. Biol.</source><year>2021</year><volume>4</volume><fpage>929</fpage><pub-id pub-id-type="doi">10.1038/s42003-021-02446-x</pub-id><pub-id pub-id-type="pmid">34330999</pub-id><pub-id pub-id-type="pmcid">PMC8324786</pub-id></element-citation></ref><ref id="B123-pathogens-11-00431"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpedo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pacheco-Fernandez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holcomb</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Lypaczewski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fultz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mishan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huston</surname><given-names>R.H.</given-names></name><etal/></person-group><article-title>Centrin-deficient <italic toggle="yes">Leishmania mexicana</italic> confers protection against New World cutaneous leishmaniasis</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00449-1</pub-id><pub-id pub-id-type="pmid">35236861</pub-id><pub-id pub-id-type="pmcid">PMC8891280</pub-id></element-citation></ref><ref id="B124-pathogens-11-00431"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Avenda&#241;o Rangel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Reis-Cunha</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Figueira</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Borba</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Viana</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Beneke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bartholomeu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>C.I.</given-names></name></person-group><article-title>Targeted Deletion of Centrin in <italic toggle="yes">Leishmania braziliensis</italic> Using CRISPR-Cas9-Based Editing</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><fpage>790418</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.790418</pub-id><pub-id pub-id-type="pmid">35252020</pub-id><pub-id pub-id-type="pmcid">PMC8892584</pub-id></element-citation></ref><ref id="B125-pathogens-11-00431"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Van Hoeven</surname><given-names>N.</given-names></name><name name-style="western"><surname>MacMillen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Picone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohamath</surname><given-names>R.</given-names></name><name name-style="western"><surname>Erasmus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Stinchcomb</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Heterologous Immunization with Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect against <italic toggle="yes">Leishmania donovani</italic></article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2420</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02420</pub-id><pub-id pub-id-type="pmid">30386348</pub-id><pub-id pub-id-type="pmcid">PMC6199377</pub-id></element-citation></ref><ref id="B126-pathogens-11-00431"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashwin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sadlova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vojtkova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becvar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lypaczewski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Greensted</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Bocxlaer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pasin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipinski</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Characterization of a new <italic toggle="yes">Leishmania major</italic> strain for use in a controlled human infection model</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>215</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-20569-3</pub-id><pub-id pub-id-type="pmid">33431825</pub-id><pub-id pub-id-type="pmcid">PMC7801518</pub-id></element-citation></ref><ref id="B127-pathogens-11-00431"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Loiseau</surname><given-names>C.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Doolan</surname><given-names>D.L.</given-names></name></person-group><article-title>Human challenge models: Tools to accelerate the development of malaria vaccines</article-title><source>Expert Rev. Vaccines</source><year>2019</year><volume>18</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1580577</pub-id><pub-id pub-id-type="pmid">30732492</pub-id></element-citation></ref><ref id="B128-pathogens-11-00431"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karmakar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hamano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matlashewski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania major</italic> centrin gene deleted parasites generate skin resident memory T cell immune response analogous to leishmanization</article-title><source>Front. Immunol.</source><year>2022</year><pub-id pub-id-type="doi">10.3389/fimmu.2022.864031</pub-id><pub-id pub-id-type="pmcid">PMC8996177</pub-id><pub-id pub-id-type="pmid">35419001</pub-id></element-citation></ref><ref id="B129-pathogens-11-00431"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valian</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Rostami</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Tasbihi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Eskandari</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Sarrafnejad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khamesipour</surname><given-names>A.</given-names></name></person-group><article-title>CCR7+ central and CCR7&#8722; effector memory CD4+ T cells in human cutaneous leishmaniasis</article-title><source>J. Clin. Immunol.</source><year>2013</year><volume>33</volume><fpage>220</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s10875-012-9788-7</pub-id><pub-id pub-id-type="pmid">22990666</pub-id></element-citation></ref><ref id="B130-pathogens-11-00431"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco-Fernandez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Volpedo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gannavaram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Satoskar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matlashewski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Revival of Leishmanization and Leishmanin</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><fpage>639801</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.639801</pub-id><pub-id pub-id-type="pmid">33816344</pub-id><pub-id pub-id-type="pmcid">PMC8010169</pub-id></element-citation></ref><ref id="B131-pathogens-11-00431"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malvolti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malhame</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mantel</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Le Rutte</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>P.M.</given-names></name></person-group><article-title>Human leishmaniasis vaccines: Use cases, target population and potential global demand</article-title><source>PLoS Negl. Trop. Dis.</source><year>2021</year><volume>15</volume><elocation-id>e0009742</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0009742</pub-id><pub-id pub-id-type="pmid">34547025</pub-id><pub-id pub-id-type="pmcid">PMC8486101</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pathogens-11-00431-f001" orientation="portrait"><label>Figure 1</label><caption><p>Immunity mediated by <italic toggle="yes">centrin</italic>-deficient live attenuated <italic toggle="yes">L. donovani</italic> mutants. (<bold>A</bold>) Immunization with <italic toggle="yes">LdCen<sup>-/-</sup></italic> leads to a significant influx of MHC-II-expressing macrophages, resulting in higher levels of IFN-&#947;+-secreting CD4+ Th1 cells and lower levels of IL-10- and IL-4-sectreting CD4+ Th2 cells. This response provides protection against needle challenge with virulent <italic toggle="yes">L. mexicana</italic> parasites. (2&#8211;4) Immunization with <italic toggle="yes">LdCen<sup>-/-</sup></italic> leads to a significant increase in IFN-&#947;- and TNF-&#945;-secreting CD4+ Th1 cells, IL-1&#946;-, IL-6-, TGF-&#946;-, and IL-23-secreting CD4+ Th17 cells, CD8+ cytotoxic T cells, Ig2a, and lower levels of IL-10-secreting CD4+ Th2 cells (<bold>B</bold>). In particular, the increase in CD4+ Th1 cells is due to an accumulation of M1 macrophages (<bold>C</bold>) and the downregulation of the CD200-CD200R axis (<bold>D</bold>). These responses, along with the accumulation of pro-inflammatory N&#945; neutrophils (<bold>E</bold>) leads to protection against needle challenge with virulent <italic toggle="yes">L. donovani</italic> parasites. Abbreviations: MHC-II: major histocompatibility complex-II.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pathogens-11-00431-g001.jpg"/></fig><fig position="float" id="pathogens-11-00431-f002" orientation="portrait"><label>Figure 2</label><caption><p>Immunity mediated by <italic toggle="yes">centrin</italic>-deficient live attenuated dermotropic <italic toggle="yes">Leishmania</italic> mutants. (<bold>A</bold>) Immunization with <italic toggle="yes">LmCen<sup>-/-</sup></italic> leads to significantly higher levels of IFN-&#947;+ effector T cells (live CD4+CD44<sup>Hi</sup>Ly6C+T-bet+) and tissue resident memory T cells (CD4+CD69+CD103+) compared to non-immunized challenged mice. These cell populations mediate protection against needle and sand fly challenge with virulent <italic toggle="yes">L. major</italic> parasites. (<bold>B</bold>) <italic toggle="yes">LmCen<sup>-/-</sup></italic> immunization also results in higher spleen expression of IFN-&#947; and TNF-&#945;, enhanced Th1 responses, and decreased Th2 responses, which mediate protection against <italic toggle="yes">L. donovani</italic> challenge. (<bold>C</bold>) In C57BL/6 mice, immunization with <italic toggle="yes">LmexCen<sup>-/-</sup></italic> leads to significantly higher Th1 responses in the skin and draining lymph nodes, compared to non-immunized controls, leading to protection against needle challenge with virulent <italic toggle="yes">L. mexicana</italic> parasites. (<bold>D</bold>) In BALB/c mice, immunization with <italic toggle="yes">LmexCen<sup>-/-</sup></italic> leads to the generation of central memory T cells (CD4+CD44+CD62L+) and to significantly lower Th2 responses in the skin and draining lymph nodes compared to non-immunized controls, leading to protection against needle challenge with virulent <italic toggle="yes">L. mexicana</italic> parasites. Abbreviations: TRM: resident memory T cells; TCM: central memory T cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pathogens-11-00431-g002.jpg"/></fig></floats-group></article></pmc-articleset>